documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrantgilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences ambisome axiceltm biktarvy cayston complera descovy emtriva epclusa eviplera genvoya gilead compass initiative harvoni hepsera letairis odefsey ranexa sovaldi stribild synnotch throttle truvada tybost vemlidy viread volibris vosevi yescartatm zydelig atripla registered trademark gilead sciences llc lexiscan registered trademark astellas us llc macugen registered trademark eyetech inc tamiflu registered trademark hoffmannla roche inc report also includes trademarks service marks trade names companiesthis annual report including section entitled managements discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forward looking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forwardlooking statements various reasons including identified part item heading risk factors given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof except required federal securities laws rules regulations securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise part item business overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world operations countries worldwide headquarters foster city california gileads primary areas focus include hivaids liver diseases hematologyoncology inflammationrespiratory diseases seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategies highlights past year continued bring bestinclass drugs market advance standard care offering enhanced modes delivery convenient treatment regimens improved resistance profiles reduced side effects greater efficacy hiv submitted new drug application nda us food drug administration fda marketing authorization application maa european medicines agency ema biktarvy oncedaily single tablet regimen containing bictegravir novel investigational integrase strand transfer inhibitor emtricitabine tenofovir alafenamide taf treatment hiv infection adults february received approval biktarvy united states oncology acquired kite pharma inc kite october shortly thereafter received fda approval yescarta axicabtagene ciloleucel first chimeric antigen receptor car cell therapy treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy acquisition kite helps establish foundation improving treatment hematological malignancies solid tumors liver diseases continued advance treatment chronic hepatitis c virus hcv infection approval vosevi sofosbuvirvelpatasvirvoxilaprevir single tablet regimen retreatment adults chronic hcv infection sovaldi sofosbuvir treatment chronic hcv infection received approval china first product launched directly china also received european commission approval vemlidy taf oncedaily treatment adults chronic hepatitis b virus hbv infection compensated liver disease addition continued advance multiple ongoing clinical studies treatment nonalcoholic steatohepatitis nash include evaluation selonsertib two ongoing phase studies area inflammationrespiratory diseases continued advance filgotinib jak inhibitor developing galapagos nv galapagos five ongoing phase clinical trials potential treatment rheumatoid arthritis crohns disease ulcerative colitis end research development pipeline included active clinical studies phase clinical trials addition advancing treatment options across therapeutic areas enabled access medications people need around world continued expand access medicines low middleincome countries pursuing multiple strategies including entering collaborations governments generic manufacturers regional business partners policy makers healthcare providers patient groups public health entities today million people receiving hiv medicines low middleincome countries entered new licensing agreement medicines patent pool mpp united nationsbacked public health organization expand access bictegravir also launched gilead compass initiative year million commitment support organizations working address hivaids epidemic southern united states hivaids goal ensure hiv patients choose single tablet regimen right single tablet regimens allow patients adhere fully suppressive course therapy easily consistently critical successful management disease hiv patients living longer thus facing additional health challenges experienced newly diagnosed patients motivated continue improving existing treatment options need efficacy together improved longterm safety driven development programs design studies completed planned taf single tablet regimens seek address diverse needs hiv patients worldwide taf novel targeted prodrug tenofovir demonstrated high antiviral efficacy similar dose less onetenth viread tenofovir disoproxil fumarate tdf well improvement surrogate laboratory markers renal bone safety compared tdf clinical trials combination antiretroviral agents recent approval launch biktarvy united states february six single tablet regimens available treatment hiv include three taf based single tablet regimens biktarvy genvoya elvitegravircobicistatemtricitabinetaf odefsey emtricitabinerilpivirinetaf expect approval biktarvy european union towards middle data four phase studies evaluating biktarvy among treatmentnave patients virologically suppressed patients found biktarvy statistically noninferior regimens containing dolutegravir combination dualnrti backbone treatmentnave patients virologically suppressed patients biktarvy also found statistically noninferior regimens containing boosted protease inhibitor virologically suppressed adult patients hiv demonstrated treatmentemergent resistance weeks continued see strong use truvada preexposure prophylaxis prep indication hiv prevention working healthcare community ensure patients providers accurate information appropriate use truvada prep launched targeted media campaigns provided grants community organizations raise awareness prep among atrisk populations education training support demonstration projects research efforts seeking identify optimal implementation strategies prep hiv prevention tool descovy currently evaluated phase clinical trials potential use prep looking ahead innovation efforts hiv continue research directed new treatment modalities pursuit ultimate goal cure liver diseases advanced treatment options standard care hcv market including providing products meet needs almost hcv patients regardless disease severity genotype prior treatment fdas approval sovaldi december compared prior standard care weeks duration treatment shortened weeks need peginterferon injections certain viral genotype populations reduced eliminated completely harvoni ledipasvirsofosbuvir approved first oncedaily single tablet regimen treatment hcv genotype infected patients prevalent genotype united states april fda approved supplemental indications sovaldi harvoni treatment hcv certain pediatric patients epclusa sofosbuvirvelpatasvir approved first alloral pangenotypic single tablet regimen treatment adults genotype chronic hcv infection epclusa also first single tablet regimen approved treatment patients hcv genotype without need ribavirin august fda approved expanded labeling epclusa include use patients coinfected hiv july fda european commission approved vosevi oncedaily single tablet regimen retreatment adults hcv offers effective cure patients failed prior therapy highly effective regimens september received regulatory approval sovaldi china estimated million people estimated living hcv also filed marketing application vemlidy treatment hbv infection china january received european commission approval vemlidy oncedaily treatment adults hbv infection compensated liver disease vemlidy approved united states november continued advance two ongoing phase studies evaluating selonsertib apoptosis signalregulating kinase ask inhibitor treatment nash expect data available positive form basis regulatory filing october announced phase data results gs acetylcoa carboxylase acc inhibitor patients nash data demonstrated gs led significant reductions measures liver fat certain biomarkers liver fibrosis compared placebo first randomized placebocontrolled phase study acc inhibitor nash study suggests gs potential play important role treating patients disease also conducting phase combination studies gs selonsertib selective nonsteroidal fxr agonist gs patients nash hematologyoncology october completed acquisition kite helped establish us leader cellular therapy provides foundation drive continued innovation people advanced cancers kites cell therapies express either car engineered cell receptor depending type cancer october yescarta car cell therapy approved fda making first car cell therapy treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy includes diffuse large bcell lymphoma dlbcl otherwise specified primary mediastinal bcell lymphoma pmbcl highgrade bcell lymphoma dlbcl arising follicular lymphoma transformed follicular lymphoma tfl expect european commission approval yescarta first half additional studies yescarta indications underway kite additional candidates clinical trials hematologic cancers solid tumors including kite car cell therapy candidate targets bcell maturation antigen patients relapsedrefractory multiple myeloma december acquired cell design labs inc cell design labs preclinical stage company significant expertise custom cell engineering company developing two proprietary technology platforms synnotch synthetic gene expression system responds external cues among applications deployed engineer car cells require dual antigen recognition activation throttle switch modulates car cell activity using small molecules addition technologies existing kite research development programs could lead treatment broader range hematological malignancies solid tumors potentially offer improved selectivity safety future treatments continued advance ongoing phase study andecaliximab mmp mab inhibitor combination mfolfox treatment gastric cancer also conducting phase study andecaliximab combination nivolumab versus nivolumab alone study expected completed first quarter inflammationrespiratory diseases continued advance five ongoing phase clinical trials filgotinib jak inhibitor developing galapagos potential treatment rheumatoid arthritis crohns disease ulcerative colitis filgotinib also investigated five phase studies treatment inflammatory diseases including psoriatic arthritis ankylosing spondylitis lupus sjogrens syndrome uveitis products hivaids biktarvy oral formulation dosed day treatment hiv infection certain patients biktarvy fixeddose combination antiretroviral medications bictegravir emtricitabine taf descovy oral formulation indicated combination antiretroviral agents treatment hiv infection adults pediatric patients years age older descovy fixeddose combination antiretroviral medications emtricitabine taf odefsey oral formulation dosed day treatment hiv infection certain patients odefsey fixeddose combination antiretroviral medications emtricitabine taf rilpivirine hydrochloride marketed janssen sciences ireland uc janssen one janssen pharmaceutical companies johnson johnson genvoya oral formulation dosed day treatment hiv infection adults genvoya single tablet regimen treatment hiv fixeddose combination antiretroviral medicines elvitegravir cobicistat emtricitabine taf stribild elvitegravircobicistatemtricitabinetdf oral formulation dosed day treatment hiv infection treatmentnave adults stribild single tablet regimen treatment hiv fixeddose combination antiretroviral medications elvitegravir cobicistat tdf emtricitabine compleraeviplera emtricitabinerilpivirinetdf oral formulation dosed day treatment hiv infection adults product marketed united states complera europe eviplera single tablet regimen treatment hiv fixeddose combination antiretroviral medications tdf emtricitabine janssens rilpivirine atripla efavirenzemtricitabinetdf oral formulation dosed day treatment hiv infection adults atripla single tablet regimen hiv intended standalone therapy combination antiretrovirals fixeddose combination antiretroviral medications tdf emtricitabine bristolmyers squibb companys bmss efavirenz truvada emtricitabinetdf oral formulation dosed day part combination therapy treat hiv infection adults fixeddose combination antiretroviral medications tdf emtricitabine fda also approved truvada prep indication combination safer sex practices reduce risk sexually acquired hiv infection adults high risk viread oral formulation nucleotide analog reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection patients two years age older european commission also approved use viread combination antiretroviral agents treatment hivinfected adolescent patients aged two less years nucleoside reverse transcriptase inhibitor resistance toxicities precluding use firstline pediatric agents viread also approved treatment hbv emtriva oral formulation nucleoside analog reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults united states europe emtriva also available oral solution approved part combination therapy treat hiv infection children tybost pharmacokinetic enhancer dosed day boosts blood levels certain hiv medicines tybost indicated boosting agent hiv protease inhibitors atazanavir darunavir part antiretroviral combination therapy adults hiv infection liver diseases vosevi oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir voxilaprevir retreatment hcv infection adults genotype previously treated nsa inhibitorcontaining regimen genotype previously treated sofosbuvircontaining regimen without nsa inhibitor vemlidy oral formulation oncedaily treatment taf adults hbv infection compensated liver disease epclusa oral formulation sofosbuvir velpatasvir first pangenotypic single tablet regimen treatment adults genotype chronic infection epclusa also first single tablet regimen approved treatment patients hcv genotype without need ribavirin epclusa weeks approved patients without cirrhosis compensated cirrhosis childpugh combination ribavirin patients decompensated cirrhosis childpugh b c fda approved expanded labeling epclusa include use patients co infected hiv harvoni oral formulation ledipasvir sofosbuvir dosed day treatment genotypes hcvhiv coinfection hcv genotype liver transplant recipients genotype infected patients decompensated cirrhosis fda approved supplemental indications harvoni treatment genotype chronic hcv infection adolescents without cirrhosis compensated cirrhosis years age older least kg europe harvoni also indicated certain patients hcv genotype infection hcv genotype infection cirrhosis andor prior treatment failure hcvhiv coinfection sovaldi oral formulation sofosbuvir dosed day treatment hcv component combination antiviral treatment regimen sovaldis efficacy established patients hcv genotypes infection united states europe genotypes infection europe including hepatocellular carcinoma meeting milan criteria awaiting liver transplantation hcvhiv co infection fda approved supplemental indications sovaldi combination ribavirin treatment genotype chronic hcv infection adolescents without cirrhosis compensated cirrhosis years age older least kg viread oral formulation nucleotide analog reverse transcriptase inhibitor dosed day treatment hbv adults compensated decompensated liver disease licensed glaxosmithkline inc gsk rights commercialize viread treatment hbv china japan saudi arabia european commission approved use viread treatment hbv infection adolescent patients aged less years compensated liver disease evidence immune active disease viread also approved treatment hiv infection hepsera adefovir dipivoxil oral formulation nucleotide analog polymerase inhibitor dosed day treat hbv patients years age older licensed gsk rights commercialize hepsera treatment hbv asia pacific latin america certain territories hematologyoncology yescarta axicabtagene ciloleucel first car cell therapy treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy including dlbcl otherwise specified pmbcl highgrade bcell lymphoma dlbcl arising tfl yescarta currently review ema potential approval expected first half zydelig idelalisib firstinclass pik delta inhibitor treatment certain blood cancers united states zydelig approved combination rituximab patients relapsed chronic lymphocytic leukemia cll rituximab alone would considered appropriate therapy monotherapy patients relapsed follicular bcell nonhodgkin lymphoma fl small lymphocytic lymphoma received least two prior systemic therapies european union zydelig approved treatment cll fl cardiovascular letairis ambrisentan oral formulation endothelin receptor antagonist indicated treatment pulmonary arterial hypertension pah group patients class ii iii symptoms improve exercise capacity delay clinical worsening sublicensed gsk rights ambrisentan marketed gsk volibris ambrisentan pah territories outside united states ranexa ranolazine extendedrelease tablet treatment chronic angina licensed menarini international operations luxembourg sa rights ranexa territories outside united states lexiscan regadenoson injection indicated use pharmacologic stress agent radionuclide myocardial perfusion imaging test detects characterizes coronary artery disease patients unable undergo adequate exercise stress astellas us llc astellas exclusive rights manufacture sell regadenoson name lexiscan united states rapidscan pharma solutions inc rps holds exclusive right manufacture sell regadenoson name rapiscan europe certain territories outside united states receive royalties astellas rps sales territories inflammationrespiratory cayston aztreonam inhalation solution inhaled antibiotic treatment respiratory systems cystic fibrosis patients seven years age older pseudomonas aeruginosa p aeruginosa tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approved treatment influenza children adults countries including united states japan european union tamiflu also approved prevention influenza children adults united states japan european union developed tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us royalties based percentage net sales tamiflu ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat serious invasive fungal infections caused various fungal species adults corporate partner astellas pharma us inc promotes sells ambisome united states canada promote sell ambisome europe australia new zealand macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelated macular degeneration macugen developed eyetech inc eyetech using technology licensed us promoted united states valeant pharmaceuticals inc valeant acquired eyetech valeant holds exclusive rights manufacture sell macugen united states pfizer inc pfizer holds exclusive rights manufacture sell macugen rest world receive royalties valeant pfizer based worldwide sales macugen antiviral product sales include sales hiv hbv hcv products billion billion billion respectively represented total revenues total revenues total revenues sales products billion billion billion respectively represented total revenues total revenues total revenues see managements discussion analysis financial condition results operations included part ii item note segment information notes consolidated financial statements included part ii item annual report additional information related sales product commercialization distribution us international commercial sales operations marketing subsidiaries countries products marketed commercial teams andor conjunction thirdparty distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant thirdparty distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory sell distribute products united states exclusively wholesale channel product sales three large wholesalers mckesson corporation amerisourcebergen corporation cardinal health inc accounted total revenues years ended december combined basis wholesalers accounted approximately product sales united states approximately total worldwide revenues sell distribute products europe countries outside united states product approved either commercial teams thirdparty distributors corporate partners us patient access make priority increase access medicines people benefit regardless ability pay united states patient support programs help patients families providing information regarding insurance coverage financial assistance eligibility free medication make therapies accessible uninsured individuals need financial assistance also support programs unable afford copayments associated commercial health insurance programs half patients taking hiv medicines united states already receive federal state programs substantially discounted prices also long history working state aids drug assistance programs adaps provide lower pricing hiv medicines price freeze instituted adaps extended end providing important support critical programs evolve changing us healthcare environment corporate giving program aims reduce disparities provide access advance education programs support local communities example launched gilead compass initiative year million commitment support organizations working address hivaids epidemic southern united states developing world access gilead access program established certain products hivaids viral hepatitis visceral leishmaniasis available substantially reduced prices developing world today million people receiving hiv medicines low middleincome countries entered number collaborations related access products developing world include licenses generic manufacturers entered voluntary license agreements generic manufacturers india south africa china allows manufacture generic versions hiv hbv products incorporating licensed compounds taf cobicistat elvitegravir bictegravir distribution certain low middleincome countries also entered licensing agreements generic manufacturers india egypt pakistan produce distribute generic versions hcv products certain low middleincome countries medicines patent pool mpp entered voluntary license agreement mpp united nationsbacked public health organization sublicense rights generic manufacturers india china south africa manufacture generic versions hiv hbv products incorporating licensed compounds taf cobicistat elvitegravir bictegravir distribution certain low middleincome countries special partnerships work national governments local organizations increase access hiv hcv medicines strengthen healthcare systems recent partnerships include partner spouses carribean leaders action network sclan address high incidence hiv region elimination mothertochild transmission raising awareness supporting hiv prevention efforts also partner organization africa first ladies hivaids oafla eliminate mothertochild transmission hiv help end aids epidemic across continent committed helping sclan oafla leaders exchange build collaborations maximizing synergies across regions supported hcv elimination program arkhangai mongolia donating enough harvoni treat entire adult population hcv prevalence government arkhangai screened treated adults course months since partnered government republic georgia us centers disease control prevention provide free hcv medicines affected disease country collaborate government healthcare professional across country expand health systems infrastructure competition marketed products target number areas including hivaids liver diseases hematologyoncology inflammationrespiratory cardiovascular diseases many commercially available products treatment diseases face significant competition large global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing products mature private insurers government payers often reduce amount reimburse patients increases pressure us reduce prices new branded generic products introduced major markets ability maintain pricing market share may affected hivaids products hiv landscape becoming competitive complex treatment trends continue evolve growing number hiv drugs currently market competition current expected competitors may erode revenues receive sales hiv products hiv products compete primarily products viiv healthcare company viiv markets fixeddose combination products compete biktarvy descovy odefsey genvoya stribild compleraeviplera atripla truvada example products marketed viiv including tivicay dolutegravir triumeq abacavirdolutegravirlamivudine juluca dolutegravirrilpivirine compete hiv products addition viivs lamivudine competes emtricitabine active pharmaceutical ingredient emtriva component biktarvy descovy odefsey genvoya stribild compleraeviplera atripla truvada tybost compete ritonavir marketed abbvie inc abbvie hiv products contain taf tdf andor emtrictabine belong nucleoside class antiviral therapeutics treatment paradigm hiv changes market share would likely decline also face competition generic hiv products generic versions lamivudine combivir lamivudine zidovudine available united states certain countries generic versions efavirenz component atripla available united states canada europe observed pricing pressure related efavirenz component atripla sales addition tdf one active pharmaceutical ingredients stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread faces generic competition european union united states certain countries addition emtricitabine active pharmaceutical ingredient truvada faces generic competition european union truvada also faces generic competition european union certain countries outside united states liver diseases products continue face competition hcv market hcv products vosevi epclusa harvoni sovaldi compete primarily mavyret glecaprevirpibrentasvir marketed abbvie zepatier elbasvir grazoprevir marketed merck co inc hcv product revenues declined expected decline result increased competition new hcv products eroded net pricing market share expect pricing pressure hcv market continue hbv products vemlidy viread hepsera face competition existing therapies treating patients hbv hbv products face competition generic versions tdf hbv products also compete baraclude entecavir oral nucleoside analog marketed bms well generic entecavir tyzekasebivo telbivudine oral nucleoside analog marketed novartis pharmaceuticals corporation novartis hematologyoncology products yescarta expected compete companies developing advanced cell therapies treatment relapsedrefractory diffuse large bcell lymphoma including novartis products letairis competes tracleer bosentan opsumit macitentan marketed actelion pharmaceuticals us inc also adcirca tadalafil marketed united therapeutics corporation pfizer letairis also expected face generic competition united states starting july ranexa competes predominantly generic compounds three distinct classes drugs treatment chronic angina united states including generic andor branded betablockers calcium channel blockers longacting nitrates ranexa also expected face generic competition united states starting addition number companies pursuing development technologies competitive existing products research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs competitors gain market share result new technologies commercialization strategies otherwise could adversely affect results operations stock price collaborative relationships part business strategy establish collaborations companies universities medical research institutions assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies universities medical research institutions information regarding certain relationships including ongoing financial accounting impact business see note collaborative arrangements notes consolidated financial statements included part ii item annual report commercial collaborations although currently number collaborations corporate partners manufacture sale distribution andor marketing products various territories worldwide following commercial collaborations significant us financial statement perspective significant ongoing collaboration activity exists bms north america entered collaboration arrangement bms develop commercialize single tablet regimen containing truvada bmss sustiva efavirenz united states canada combination approved use united states sold brand name atripla bms structured collaboration joint venture operated limited liability company consolidated bms granted royaltyfree sublicenses joint venture use respective company owned technologies return granted certain licenses joint venture use intellectual property resulting collaboration economic interests joint venture held us bms including sharing revenues outofpocket expenses based portion net selling price atripla attributable truvada efavirenz since net selling price truvada changed time relative net selling price efavirenz bmss respective economic interests joint venture varied annually course collaboration agreement either party could terminate partys participation collaboration within days launch least one generic version partys single agent products double agent products terminating party right continue sell atripla become continuing party obligated pay terminated party certain royalties threeyear period following effective date termination december generic version efavirenz launched united states upon generic version launch terminated bmss participation collaboration became continuing party sole owner joint venture december last day collaboration result termination transfer gilead bmss ownership interest joint venture consolidate limited liability company whollyowned subsidiary bms longer ownership interest joint venture permitted commercialize atripla united states canada entitled receive us certain royalties net sales atripla next three calendar years declining annual scale may continue purchase efavirenz bms needed continue manufacturing atripla united states canada markets europe gilead sciences ireland uc whollyowned subsidiary bms entered collaboration agreement sets forth terms conditions bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bmss estimated net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehousing local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling sales returns territories bms promote atripla general parties share revenues outofpocket expenses proportion net selling prices components atripla truvada efavirenz starting except limited number activities jointly managed parties longer coordinate detailing promotional activities european territory responsible accounting financial reporting tax reporting collaboration december efavirenz purchased bms bmss estimated net selling price efavirenz european territory included inventories consolidated balance sheets parties also formed limited liability company hold marketing authorization atripla european territory primary responsibility regulatory activities major market countries parties agreed independently continue use commercially reasonable efforts promote atripla agreement terminate upon expiration lasttoexpire patent affords market exclusivity atripla one components european territory addition since december either party may terminate agreement reason termination effective two calendar quarters notice termination nonterminating party right continue sell atripla become continuing party obligated pay terminating party certain royalties threeyear period following effective date termination event continuing party decides sell atripla effective date termination date atripla withdrawn country date third party assumes distribution atripla whichever earlier janssen entered license collaboration agreement janssen sciences ireland uc janssen formerly tibotec pharmaceuticals develop commercialize fixeddose combination truvada janssens nonnucleoside reverse transcriptase inhibitor rilpivirine combination approved united states european union sold brand name complera united states eviplera european union original agreement janssen granted us exclusive license compleraeviplera worldwide excluding certain middle income developing world countries japan responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization products except countries janssen distributes janssen exercised right codetail combination product countries gilead selling party either party may terminate collaboration agreement respect product country product withdrawn market country respect product countries party materially breaches agreement respect product agreement parties obligation share revenues expire productbyproduct countrybycountry basis janssen patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement without cause respect countries sell products case janssen right become selling party country product launched market fewer years japan tobacco japan tobacco inc japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retained rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize elvitegravir treatment hiv infection bear costs expenses associated commercialization efforts received approval stribild elvitegravircontaining product fda august european commission may received approval genvoya elvitegravircontaining product fda european commission november agreement obligation pay royalties japan tobacco terminate productbyproduct basis patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement reason case license granted japan tobacco us would terminate either party may terminate agreement response material breach party research collaborations number collaborations partners research development rd certain compounds drug candidates none research collaborations significant us financial statement perspective research development rd philosophy strategy develop bestinclass drugs improve safety efficacy unmet medical needs intend continue committing significant resources internal rd opportunities external business development activity product development efforts cover wide range medical conditions including hivaids liver diseases hematologyoncology inflammationrespiratory diseases research scientists primarily foster city santa monica california seattle washington alberta canada engaged discovery development new molecules technologies hope lead approval new medicines advance current standard care address unmet medical needs development product candidates subject various risks uncertainties risks uncertainties include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain regulatory approvals result product candidates may never successfully commercialized drug development inherently risky many product candidates fail drug development process summary key product candidates corresponding current stages development product candidates treatment hivaids product candidates description product phase descovy descovy evaluated prep indication products phase gs gs tlr agonist evaluated treatment hiv infection gs gs broadly neutralizing antibody bnab evaluated treatment hiv infection product candidates treatment liver diseases product candidates description product phase selonsertib selonsertib ask inhibitor evaluated treatment nash products phase selonsertib selonsertib evaluated treatment alcoholic hepatitis gs gs acc inhibitor evaluated treatment nash gs gs fxr agonist evaluated treatment nash primary biliary cirrhosis primary sclerosing cholangitis product phase gs gs tlr agonist evaluated treatment hbv infection product candidates treatment hematologyoncology product candidates description products phase andecaliximab andecaliximab mmp mab inhibitor evaluated treatment gastric cancer axicabtagene ciloleucel axicabtagene ciloleucel evaluated treatment second line diffuse large bcell lymphoma idelalisib idelalisib pik delta inhibitor evaluated treatment relapsed refractory chronic lymphocytic leukemia products phase axicabtagene ciloleucel axicabtagene ciloleucel evaluated treatment indolent nonhodgkin lymphoma axicabtagene ciloleucel also evaluated treatment diffuse large bcell lymphoma combination anti pdl mab entospletinib entospletinib syk inhibitor evaluated treatment hematological malignancies tirabrutinib tirabrutinib btk inhibitor evaluated treatment bcell malignancies ktec ktec car cell therapy evaluated treatment mantle cell lymphoma products phase andecaliximab andecaliximab evaluated treatment solid tumors gs gs bet inhibitor evaluated treatment solid tumors ktec ktec evaluated treatment adult pediatric acute lymphoblastic leukemia kite kite antibcma evaluated treatment multiple myeloma kite kite mage aa evaluated treatment solid tumors product candidates treatment inflammationrespiratory diseases product candidates description product phase filgotinib filgotinib jak inhibitor evaluated treatment rheumatoid arthritis crohns disease ulcerative colitis products phase filgotinib filgotinib evaluated treatment various inflammatory diseases presatovir presatovir fusion inhibitor evaluated treatment respiratory syncytial virus gs gs syk inhibitor evaluated treatment sjogrens syndrome lupus product candidates product candidate description product phase gs gs nuc inhibitor evaluated treatment ebola virus infection total rd expenses billion billion billion rd expenses decreased compared primarily due impacts business development activities resulting upfront collaboration expense related license collaboration agreement galapagos acquired inprocess rd iprd expense related purchase nimbus apollo inc nimbus iprd impairment charges ongoing milestone payments partially offset acquired iprd expense related purchase cell design labs addition internal discovery clinical development programs seek add portfolio products product acquisitions licenses collaborations acquired kite shortly thereafter received fda approval axicabtagene ciloleucel known commercially yescarta making first car cell therapy treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy includes dlbcl tfl pmbcl expect european commission approval yescarta first half additional studies yescarta indications underway kite additional candidates clinical trials hematologic cancers solid tumors including kite car cell therapy candidate targets bcell maturation antigen patients relapsedrefractory multiple myeloma also acquired cell design labs preclinical stage company significant expertise custom cell engineering company developing two proprietary technology platforms synnotch synthetic gene expression system responds external cues among applications deployed engineer car cells require dual antigen recognition activation throttle switch modulates car cell activity using small molecules addition technologies existing kite research development programs could lead treatment broader range hematological malignancies solid tumors potentially offer improved selectivity safety future treatments patents proprietary rights us european patent expiration number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted united states european union primary typically compound patents phase product candidates product candidates single tablet regimens estimated patent expiration date provided corresponds latest expiring compound patent one active ingredients single tablet regimen phase product candidates patent expiration product candidate treatment hiv us eu descovy prep product candidate treatment liver diseases selonsertib treatment nash product candidates treatment hematologyoncology andecaliximab treatment gastric cancer axicabtagene ciloleucel treatment second line diffuse large bcell lymphoma idelalisib treatment relapsed refractory cll product candidate treatment inflammationrespiratory diseases filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis dates parentheses reflect estimated expiration date patents may issue currently pending applications estimated expiration dates include potential additional exclusivity eg patent term extensions supplementary protection certificates pediatric exclusivity yet granted composition matter patent expired european union european union united states patent applications pending relating kites proprietary manufacturing processes following table shows actual estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted united states european union primary typically compound patents marketed products patents cover ranolazine active ingredient ranexa instead discovered sustainedrelease formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve products fixeddose combinations single tablet regimens eg truvada atripla compleraeviplera stribild genvoya odefsey descovy biktarvy estimated patent expiration dates provided correspond latest expiring compound patent one active ingredients single tablet regimen products patent expiration us eu letairis viread ranexa atripla cayston emtriva truvada lexiscan descovy vemlidy compleraeviplera zydelig odefsey yescarta sovaldi stribild genvoya tybost harvoni epclusa biktarvy vosevi estimated expiration dates include potential additional exclusivity eg patent term extensions supplementary protection certificates pediatric exclusivity yet granted gilead watson laboratories inc reached agreement settle patent litigation related letairis gilead teva pharmaceuticals teva reached agreement principle settle ongoing patent litigation concerning four patents protect tenofovir disoproxil fumarate viread truvada atripla products agreement teva allowed launch generic version viread december gilead lupin limited lupin reached agreement settle patent litigation prior issuance courts decision agreement lupin allowed launch generic version ranexa february gilead teva reached agreement settle patent litigation concerning patents protect emtricitabine truvada atripla products supplementary protection certificates spcs granted several european countries validity spcs challenged several generic manufacturers many launched conpeting product validity spcs considered national courts court justice european union composition matter patent expired european union european union united states patent applications pending relating kites proprietary manufacturing processes applications patent term extensions pending united states andor spcs pending one countries european union products application patent term extension filed united states granted would extend us expiration date applications spcs filed european union granted would extend eu expiration date patent protection certain challenges patents proprietary rights important business properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology patents covering certain active pharmaceutical ingredients api hiv products well yescarta letairis ranexa held third parties acquired exclusive rights patents agreements parties patents covering ranolazine active ingredient ranexa instead discovered sustainedrelease formulation ranolazine would achieve therapeutic plasma levels obtained patents formulations characteristic plasma levels achieve yescarta composition matter patent expired european union european union united states patent applications pending related kites proprietary manufacturing processes may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions supplementary protection certificates countries example extensions patents supplementary protection certificates many products granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain countries also important infringe valid patents third parties infringe valid patents third parties may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned parties parties may claim cover use sofosbuvir axicabtagene ciloleucel bictegravir patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate interferencederivation proceedings litigation determine right patent litigation interferencederivation proceedings unpredictable expensive even ultimately successful results operations may adversely affected events patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation proceedings regarding enforcement validity existing patents future patents could result invalidation patents substantially reduce protection time time certain individuals entities may challenge patents pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products closely related developed developing addition certain countries provide effective enforcement patents thirdparty manufacturers may able sell generic versions products countries description significant pending legal proceedings please see note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report trade secrets also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions trade secrets confidential information become known independently discovered competitors enter disputes ownership inventions business results operations could adversely affected manufacturing raw materials products either manufactured facilities thirdparty manufacturers corporate partners depend third parties manufacture majority api solid dose products also rely corporate partners manufacture certain products additionally lease manufacturing facilities foster city san dimas la verne oceanside el segundo california edmonton alberta canada cork ireland manufacture certain products api clinical andor commercial uses manufacturing products contract third parties manufacture certain api clinical commercial purposes including vosevi epclusa harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya odefsey descovy biktarvy vemlidy emtriva tybost ranexa ambisome zydelig cayston generally use multiple thirdparty contract manufacturers manufacture api products exclusive manufacturer ambrisentan api letairis although another supplier qualified make api also rely thirdparty contract manufacturers manufacture oral liquid tablet capsule products example use multiple thirdparty contract manufacturers manufacture epclusa harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya odefsey descovy biktarvy vemlidy ranexa emtriva vosevi tybost letairis zydelig hepsera also completed thirdparty contract manufacturer addition rely thirdparty contract manufacturers manufacture aseptic products ambisome cayston established clinical commercial manufacturing facility cell processing activities yescarta yescarta car cell therapy involves harvesting cells patients blood ii engineering cells express cancerspecific receptors iii increasing number engineered cells iv infusing functional cancerspecific cells back patient future products continue develop additional manufacturing capabilities establish additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale manufacturing facilities foster city california facility conduct process chemistry research development activities manufacture api clinical trials oversee thirdparty contract manufacturers san dimas california la verne california facilities manufacture ambisome san dimas package label majority commercial products distribute products americas pacific rim utilize oceanside california facility clinical manufacture process development biologics candidates preclinical phase phase testing utilize el segundo california facility clinical commercial manufacture processing yescarta patientbypatient basis utilize cork ireland facility commercial manufacture packaging labeling antiviral products also perform quality control testing labeling packaging final release many products distribution european union international markets edmonton alberta facility canada carry process research scaleup clinical development candidates manufacture api investigational commercial products conduct chemical development activities improve existing commercial manufacturing processes thirdparty manufacturers thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval may writeoff costs manufacturing batch fails pass quality inspection meet regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected addition thirdparty manufacturers corporate partners may able produce products one limited number facilities therefore limited manufacturing capacity certain products believe technology use manufacture products proprietary products manufactured thirdparty contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements thirdparty manufacturers intended restrict manufacturers using revealing technology certain thirdparty manufacturers comply restrictions addition thirdparty manufacturers could develop technology related work perform us may need manufacture products could required enter additional agreements thirdparty manufacturers want use technology allow another manufacturer use technology thirdparty manufacturer could refuse allow us use technology could demand terms use technology acceptable us regulation manufacturing process manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations thirdparty manufacturers corporate partners subject current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda ema similar regulations effect jurisdictions manufacturing operations subject routine inspections regulatory agencies unable remedy deficiencies cited fda inspections currently marketed products timing regulatory approval products development could adversely affected risk regulatory agencies countries marketing applications pending undertake similar additional reviews apply heightened standard review could delay regulatory approvals products countries yescarta required fda comply risk evaluation mitigation strategy program includes educating certifying medical personnel regarding therapy procedures potential side effect profile therapy potential adverse side effects related cytokine release syndrome neurologic toxicities additionally required maintain complex chain identity custody respect patient material material moves manufacturing facilities manufacturing process back patient access supplies materials need access certain supplies products conduct clinical trials manufacture products unable purchase sufficient quantities materials find suitable alternate materials timely manner development efforts product candidates may delayed ability manufacture products would limited would limit ability generate revenues example significant portion raw materials intermediates used manufacture antiviral products supplied thirdparty manufacturers corporate partners outside united states result political economic factors specific country region including changes interpretations trade regulations compliance requirements tax legislation would limit prevent third parties outside united states supplying materials would adversely affect ability manufacture supply antiviral products meet market needs material adverse effect operating results seasonal operations backlog worldwide product sales reflect significant degree seasonality part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states countries united states european union countries drugs subject rigorous regulation federal state statutes regulations govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming regulatory requirements applicable drug development approval subject change legal regulatory changes may impact operations future countrys regulatory agency fda united states emaeuropean commission european union must approve drug sold respective country countries general process drug approval united states summarized many countries including countries european union similar regulatory structures preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidates potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous phase clinical trials phase drug candidate appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data clinical trials show acceptable benefitrisk profile submit appropriate filing usually form nda supplemental nda fda seeking approval sell drug candidate particular use fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety efficacy particular use allow us sell drug candidate united states use unusual however fda reject application believes drug candidate safe enough efficacious enough believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california including el segundo la verne oceanside san dimas facilities also must licensed state california compliance local regulatory requirements edmonton alberta manufacturing facility canada facilities located near dublin cork ireland also must obtain local licenses permits compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track candidates fda may eligible priority review drugs treatment hiv infection designated use us presidents emergency plan aids relief may also qualify expedited priority review rest world drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union includes major countries europe centralized approval procedure used approval one country european union used obtain approval another country european union one two simplified application processes mutual recognition procedure decentralized procedure rely principle mutual recognition receiving regulatory approval european registration procedures separate pricing reimbursement approvals also required countries european union also requirements approval manufacturing facilities products approved sale european regulatory authorities pricing reimbursement successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments markets sell products government health authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services significant portion sales majority products subject substantial discounts list price addition nonretail sector united states includes government institutions including state adaps us department veterans affairs correctional facilities large health maintenance organizations tends even less consistent terms buying patterns often causes quarteroverquarter fluctuations necessarily mirror patient demand products federal state budget pressures including sequestration well annual grant cycles federal state funds may cause purchasing patterns reflect patient demand products example first quarters certain prior years observed large nonretail purchases hiv products number state adaps exceeded patient demand believe purchases driven grant cycle federal adap funds expect continue experience fluctuations purchasing patterns nonretail customers may result fluctuations product sales revenues earnings future light budget crises faced many european countries observed variations purchasing patterns induced cost containment measures europe believe measures caused government agencies purchasers reduce inventory products distribution channels decreased revenues caused fluctuations product sales earnings may continue see trend future products mature private insurers government payers often reduce amount reimburse patients increases pressure us reduce prices new branded generic products introduced major markets ability maintain pricing market share may affected example tdf one active pharmaceutical ingredients stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread faces generic competition european union united states certain countries addition emtricitabine active pharmaceutical ingredient truvada faces generic competition european union truvada also faces generic competition european union certain countries outside united states negative impact business results operations see also item risk factor substantial portion revenues derived sales products treat hiv hcv unable increase hiv sales hcv sales decrease anticipated results operations may adversely affected patient assistance programs recently enhanced scrutiny companysponsored patient assistance programs including insurance premium copay assistance programs donations thirdparty charities provide assistance also enhanced scrutiny governments reimbursement support offerings clinical education programs promotional speaker programs agents vendors donation recipients deemed failed comply laws regulations government guidance areas could subject criminal civil sanctions similar violations competitors could also negatively impact industry reputation increase scrutiny business products see also item risk factor laws regulations applicable health care industry could impose new obligations us require us change business practices restrict operations future united states healthcare reform legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions united states along pharmaceutical manufacturers branded drug products required pay portion industry fee also known branded prescription drug bpd fee calculated based select government sales year percentage total industry government sales amount annual bpd fee imposed pharmaceutical industry whole billion billion thereafter bpd fee expenses million million million bpd fee tax deductible since november us election president trump us congress made numerous efforts repeal amend affordable care act whole part may us house representatives voted pass american health care act ahca would repeal many provisions affordable care act although us senate considered failed pass ahca comparable measures us congress may consider legislation repeal replace elements affordable care act addition tax cuts jobs act president trump signed law december repeals affordable care acts individual health insurance mandate considered key component affordable care act future stability affordable care act resulting impact business thus uncertain could material addition many states proposed legislation seeks indirectly directly regulate pharmaceutical drug pricing requiring biopharmaceutical manufacturers publicly report proprietary pricing information place maximum price ceiling pharmaceutical products purchased state agencies proposed legislation passed may experience additional pricing pressures products example october californias governor signed prescription drug price transparency state bill law requiring prescription drug manufacturers provide advance notice explanation price increases certain drugs exceed specified threshold similar bills previously introduced federal level expect additional legislation may introduced year potential effect health insurance market destabilization ongoing repeal replace discussions well impact potential changes way medicaid program financed likely affect patients sources insurance resultant drug coverage discussions continue federal level regarding policies would either allow require us government directly negotiate drug prices pharmaceutical manufacturers medicare patients require manufacturers pay higher rebates medicare part give states flexibility drugs covered medicaid program policy proposals could impact reimbursement products discussions centered legislation would permit reimportation prescription medications canada countries difficult predict impact legislation executive actions medicaid flexibility use reimbursement products united states including potential importation generic versions products yescarta administered inpatient basis possible federal government reimbursement programs like medicare medicaid insufficient cover complete cost associated therapy could impact willingness hospitals offer therapy doctors recommend therapy could lessen attractiveness therapy patients could adverse effect sales yescarta results operations addition state medicaid programs could request additional supplemental rebates products result increase federal base medicaid rebate private insurers could also use enactment increased rebates exert pricing pressure products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules health care fraud abuse laws antibribery laws subject various federal state laws pertaining health care fraud abuse including antikickback laws false claims laws antikickback laws make illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions increasing attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws generally prohibit anyone knowingly presenting causing presented false fraudulent claim payment federal certain state payers including medicare medicaid knowingly making using causing made used false record statement material false fraudulent claim sales marketing patient support medical activities may subject scrutiny laws addition us foreign corrupt practices act similar worldwide antibribery laws generally prohibit companies intermediaries making improper payments purpose obtaining retaining business policies mandate compliance antibribery laws operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different local custom despite training compliance program internal control policies procedures may protect us reckless criminal acts committed employees agents violations fraud abuse laws antibribery laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid violations also lead imposition corporate integrity agreement similar government oversight program government allege convict us violating laws could disruption business material adverse effect results operations compulsory licenses number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv hcv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example growing attention availability hcv therapies activists advocating increased availability hcv therapies means including compulsory licenses government malaysia exercised government rights section malaysian patents act practice patented invention sofosbuvir period three years use government hospitals clinics challenging malaysian governments actions past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread compulsory licenses permit generic manufacturing override product patents hiv hcv products required grant compulsory licenses products could reduce earnings cash flows harm business addition certain countries permit enforcement patents permit patents issue thirdparty manufacturers able sell generic versions products countries example brazilian health regulatory agency rejected patent applications related sofosbuvir hcv products successfully appealed decisions applications examination brazilian patent trademark office sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales employees january approximately employees believe good relations employees environment health safety strive reduce environmental footprint implement sustainable business process practices incorporate sustainability throughout development distribution medicines safety regulatory compliance products regular efficiency improvements make manufacturing processes operations surrounding product portfolio routinely evaluated new innovative ways incorporate social environmental responsibility practices include ethical sourcing materials green chemistry practices solvent recycling continued improvements sustainability efficiency api product development process gilead sites around world identify opportunities reduce natural resource usage water conservation sustainable building practices energy conservation recycling diversion landfill alternative transportation continue look ways minimize impact environment factors contribute environmental impact include greenhouse gas emissions produced employee commutes energy water consumed facilities use hazardous materials chemicals viruses radioactive compounds rd facilities please refer year review found website wwwgileadcom responsibility measures taken mitigate environmental impact business subject number laws regulations require compliance federal state local regulations regarding workplace safety protection environment anticipate additional regulations near future laws regulations implemented consideration mitigate effects climate change mainly caused greenhouse gas emissions business energy intensive therefore anticipate subject cap trade system mitigation measure would materially impact capital expenditures operations competitive position based current information subject finalization proposed regulations believe primary risk related climate change increased energy costs information subject information requirements exchange act therefore file periodic reports proxy statements information sec reports proxy statements information may obtained visiting public reference room sec f street ne washington dc calling sec sec sending electronic message sec publicinfosecgov sending fax sec addition sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings section make available following filings soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act filings available free charge upon request transactions iran transactions iran would require disclosure annual report item risk factors evaluating business carefully consider following risks addition information annual report manifestation following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider following risks complete statement potential risks uncertainties face substantial portion revenues derived sales products treat hiv hcv unable increase hiv sales hcv sales decrease anticipated results operations may adversely affected receive substantial portion revenue sales products treatment hiv infection include genvoya truvada atripla descovy stribild odefsey compleraeviplera year ended december sales hiv products accounted approximately total product sales expect hiv products account higher percentage total product sales hiv products contain tenofovir alafenamide taf tenofovir disoproxil fumarate tdf andor emtricitabine belong nucleoside class antiviral therapeutics treatment paradigm hiv changes causing nucleosidebased therapeutics fall favor unable maintain increase hiv product sales results operations would likely suffer would likely need scale back operations including spending research development efforts year ended december sales harvoni epclusa sovaldi vosevi treatment hcv accounted approximately total product sales primary drivers hcv product revenues patient starts net pricing market share since second quarter number new patient starts diminished expect patient starts continue decline relative major markets resulting decrease hcv product sales hcv revenues declined expected decline result increased competition new hcv products eroded net pricing market share anticipate impact pricing market share fully reflected mid hcv product sales could also impacted larger anticipated shift payer mix highly discounted payer segments geographic regions addition future sales hcv products may difficult estimate demand depends part extent reimbursement hcv products private government payers may continue experience global pricing pressure could result larger discounts rebates products delayed reimbursement negatively impacts product sales results operations also private public payers choose exclude hcv products formulary coverage lists limit types patients coverage provided would negatively impact demand revenues hcv products change formulary coverage reimbursement levels discounts rebates offered hcv products payers may impact anticipated revenues expect pricing pressure hcv market continue unable achieve forecasted hcv sales stock price could experience significant volatility may unable sustain increase sales hiv hcv products number reasons including limited reasons discussed following hiv hcv products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings contraindications labels narrow approved indications halt sales product could reduce revenues products mature private insurers government payers often reduce amount reimburse patients products increases pressure us reduce prices physicians see benefit hiv hcv products sales hiv hcv products limited new branded generic products introduced major markets ability maintain pricing market share may affected example tdf one active pharmaceutical ingredients stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread faces generic competition european union united states certain countries addition emtricitabine active pharmaceutical ingredient truvada faces generic competition european union truvada faces generic competition european union certain countries outside united states expected continue negative impact business results operations fail commercialize new products expand indications existing products prospects future revenues may adversely affected introduce new products increase sales existing products able increase maintain total revenues continue expand rd efforts drug development inherently risky many product candidates fail drug development process example terminated phase studies gs treatment rheumatoid arthritis cystic fibrosis phase study gs treatment hepatitis b virus addition may decide terminate product development expending significant resources effort addition unable obtain regulatory approval product candidates recent acquisition kite pharma inc kite effectively commercialize kites product candidates may able realize anticipated benefits acquisition kite including expected future revenues kites product candidates filed marketing authorization application maa european union approval oncedaily single tablet regimen containing bictegravir mg emtricitabinetenofovir alafenamide mg treatment hiv infection adults also filed maa european union approval axicabtagene ciloleucel treatment relapsedrefractory diffuse large bcell lymphoma transformed follicular lymphoma primary mediastinal bcell lymphoma future marketing applications file may approved regulatory authorities timely basis even marketing approval granted products may significant limitations use may unable file marketing applications new products inability accurately predict demand products uptake new products fluctuations customer inventories makes difficult us accurately forecast sales may cause forecasted revenues earnings fluctuate could adversely affect financial results stock price may unable accurately predict demand products including uptake new products demand dependent number factors example nonretail sector united states includes government institutions including state aids drug assistance programs adaps us department veterans affairs correctional facilities large health maintenance organizations tends even less consistent terms buying patterns often causes quarteroverquarter fluctuations necessarily mirror patient demand products federal state budget pressures well annual grant cycles federal state funds may cause purchasing patterns reflect patient demand products example first quarters certain prior years observed large nonretail purchases hiv products number state adaps exceeded patient demand believe purchases driven grant cycle federal adap funds expect continue experience fluctuations purchasing patterns nonretail customers may result fluctuations product sales revenues earnings future light budget crises faced many european countries observed variations purchasing patterns induced cost containment measures europe believe measures caused government agencies purchasers reduce inventory products distribution channels decreased revenues caused fluctuations product sales earnings may continue see trend future year ended december approximately product sales united states three wholesalers mckesson corp amerisourcebergen corp cardinal health inc us wholesalers entered inventory management agreements make estimates determine end user demand may completely effective matching inventory levels actual end user demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand addition inventory held retail pharmacies nonwholesaler locations inventory management agreements control buying patterns adverse changes economic conditions increased competition factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers orders us even end user demand changed example fourth quarter strong wholesaler subwholesaler purchases products resulted inventory drawdown wholesalers subwholesalers first quarter inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues hcv products represent cure competitors hcv products entered market revenues hcv products difficult us investors estimate primary drivers hcv product revenues patient starts net pricing market share experience number patient starts difficult accurately predict addition demand hcv products depend extent reimbursement hcv products private public payers united states countries private public payers choose exclude hcv products formulary coverage lists limit types patients coverage provided would negatively impact demand revenues hcv products continue experience pricing pressure united states european union countries change formulary coverage reimbursement levels discounts rebates offered hcv products payers may negatively impact anticipated revenues addition rebate claims product discounts made payers one two quarters arrears estimate rebates required pay connection sales particular quarter based claims data prior quarters hcvrelated revenues difficult predict investors may widely varying expectations may materially higher lower actual anticipated revenues extent actual anticipated hcv product revenues exceed fall short expectations stock price may experience significant volatility yescarta chimeric antigen receptor car cell therapy represents novel approach cancer treatment creates significant challenges us yescarta car cell therapy involves harvesting cells patients blood ii engineering cells express cancerspecific receptors iii increasing number engineered cells iv infusing functional cancerspecific cells back patient advancing novel personalized therapy creates significant challenges including educating certifying medical personnel regarding procedures potential side effect profile therapy potential adverse side effects related cytokine release syndrome neurologic toxicities compliance risk evaluation mitigation strategy rems program required fda yescarta using medicines manage adverse side effects therapy tocilizumab corticosteroids may available sufficient quantities may adequately control side effects andor may detrimental impact efficacy treatment sourcing clinical commercial supplies materials used manufacture process yescarta developing robust reliable process limiting contamination risks engineering patients cells ex vivo infusing engineered cells back patient conditioning patients chemotherapy advance administering therapy may increase risk adverse side effects use engineered cells potential cancer treatment recent development may broadly accepted physicians patients hospitals cancer treatment centers payers others medical community may able establish demonstrate medical community safety efficacy yescarta potential advantages side effects compared existing future therapeutics fail overcome significant challenges sales yescarta results operations stock price could adversely affected may required pay significant damages merck co inc merck result jurys finding willfully infringed patent owned mercks idenix subsidiary december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringe idenixs us patent patent interference exists patent us patent also december idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringe us patent nos patent patent june court transferred massachusetts litigation us district court district delaware idenix acquired merck august prior trial december idenix committed give us covenant sue respect claims arising patent related sofosbuvir withdrew patent trial addition idenix declined litigate patent infringement action trial light appeal pending us court appeals federal circuit cafc regarding first invent subject matter claimed patent january district court stayed idenixs infringement claim patent pending outcome appeal interference decision patent second idenix interference described unless idenix successful persuading united states supreme court consider appeal challenge federal circuits june decision favor second idenix interference ask dismissal judgment entered idenix infringement interference claims jury trial held december patent december jury found willfully infringed asserted claims patent awarded idenix billion past damages parties filed posttrial motions briefings district judge heard oral argument september september judge denied idenixs motions enhanced damages attorneys fees february judge granted motion arguing patent invalid lacking enablement grant motion invalidating idenixs patent vacates jurys award billion past damages idenix indicated plans appeal decision cafc believe courts decision correctly found matter law patent invalid remain confident merits case appeal courts decision invalidating idenixs patent overturned appeal amount could required pay could material timing magnitude amount payment could material adverse impact results operations stock price results operations may adversely affected current potential future healthcare reforms legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions united states along pharmaceutical manufacturers branded drug products required pay portion industry fee also known branded prescription drug bpd fee calculated based select government sales year percentage total industry government sales amount annual bpd fee imposed pharmaceutical industry whole billion billion thereafter bpd fee expenses million million million bpd fee tax deductible since november us election president trump us congress made numerous efforts repeal amend affordable care act whole part may us house representatives voted pass american health care act ahca would repeal many provisions affordable care act although us senate considered failed pass ahca comparable measures us congress may consider legislation repeal replace elements affordable care act addition tax cuts jobs act president trump signed law december repeals affordable care acts individual health insurance mandate considered key component affordable care act future stability affordable care act resulting impact business thus uncertain could material addition many states proposed legislation seeks indirectly directly regulate pharmaceutical drug pricing requiring biopharmaceutical manufacturers publicly report proprietary pricing information place maximum price ceiling pharmaceutical products purchased state agencies proposed legislation passed may experience additional pricing pressures products example october californias governor signed prescription drug price transparency state bill law requiring prescription drug manufacturers provide advance notice explanation price increases certain drugs exceed specified threshold similar bills previously introduced federal level expect additional legislation may introduced year potential effect health insurance market destabilization ongoing repeal replace discussions well impact potential changes way medicaid program financed likely affect patients sources insurance resultant drug coverage discussions continue federal level regarding policies would either allow require us government directly negotiate drug prices pharmaceutical manufacturers medicare patients require manufacturers pay higher rebates medicare part give states flexibility drugs covered medicaid program policy proposals could impact reimbursement products discussions centered legislation would permit reimportation prescription medications canada countries difficult predict impact legislation executive actions medicaid flexibility use reimbursement products united states including potential importation generic versions products yescarta administered inpatient basis possible federal government reimbursement programs like medicare medicaid insufficient cover complete cost associated therapy could impact willingness hospitals offer therapy doctors recommend therapy could lessen attractiveness therapy patients could adverse effect sales yescarta results operations addition state medicaid programs could request additional supplemental rebates products result increase federal base medicaid rebate private insurers could also use enactment increased rebates exert pricing pressure products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments markets sell products government health authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services significant portion sales majority products subject significant discounts list price face significant competition face significant competition global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing hiv products compete primarily products viiv healthcare company viiv markets fixeddose combination products compete biktarvy descovy odefsey genvoya stribild compleraeviplera atripla truvada example products marketed viiv including tivicay dolutegravir triumeq abacavirdolutegravirlamivudine juluca dolutegravirrilpivirine compete hiv products addition lamivudine marketed viiv competes emtricitabine active pharmaceutical ingredient emtriva component biktarvy descovy odefsey genvoya stribild compleraeviplera atripla truvada tybost compete ritonavir marketed abbvie inc abbvie also face competition generic hiv products generic versions lamivudine combivir lamivudine zidovudine available united states certain countries generic versions efavirenz component atripla available united states canada europe observed pricing pressure related efavirenz component atripla sales tdf one active pharmaceutical ingredients stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread faces generic competition european union united states certain countries addition emtricitabine active pharmaceutical ingredient truvada faces generic competition european union truvada also faces generic competition european union certain countries outside united states hcv products sovaldi harvoni epclusa vosevi compete primarily mavyret glecaprevirpibrentasvir marketed abbvie zepatier elbasvir grazoprevir marketed merck hbv products vemlidy viread hepsera face competition existing therapies treating patients hbv hbv products face competition generic versions tdf hbv products also compete baraclude entecavir oral nucleoside analog marketed bristolmyers squibb company bms well generic entecavir tyzekasebivo telbivudine oral nucleoside analog marketed novartis pharmaceuticals corporation novartis yescarta expected compete companies developing advanced cell therapies treatment relapsedrefractory diffuse large bcell lymphoma including novartis letairis competes tracleer bosentan opsumit macitentan marketed actelion pharmaceuticals us inc also adcirca tadalafil marketed united therapeutics corporation pfizer inc letairis also expected face generic competition united states starting july ranexa competes predominantly generic compounds three distinct classes drugs treatment chronic angina united states including generic andor branded betablockers calcium channel blockers longacting nitrates ranexa also expected face generic competition united states starting addition number companies pursuing development technologies competitive existing products research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs competitors gain market share result new technologies commercialization strategies otherwise could adversely affect results operations stock price laws regulations applicable health care industry could impose new obligations us require us change business practices restrict operations future health care industry subject various federal state international laws regulations pertaining drug reimbursement rebates price reporting health care fraud abuse data privacy security united states laws include antikickback false claims laws laws regulations relating medicare medicaid programs federal state programs medicaid rebate statute individual state laws relating pricing sales marketing practices health insurance portability accountability act hipaa federal state laws relating privacy security health information violations laws related regulations may punishable criminal andor civil sanctions including instances substantial fines civil monetary penalties exclusion participation federal state health care programs including medicare medicaid veterans administration health programs federal employee health benefit programs actions executives overseeing business burdensome remediation measures addition laws regulations broad scope subject change evolving interpretations could require us incur substantial costs associated compliance alter one sales marketing practices violations laws allegations violations could also result negative publicity consequences could harm reputation disrupt business adversely affect results operations events occur business stock price could materially adversely affected recently enhanced scrutiny companysponsored patient assistance programs including insurance premium copay assistance programs donations thirdparty charities provide assistance also enhanced scrutiny governments reimbursement support offerings clinical education programs promotional speaker programs agents vendors donation recipients deemed failed comply laws regulations government guidance areas could subject criminal civil sanctions similar violations competitors could also negatively impact industry reputation increase scrutiny business products see description government investigations related litigation note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report approximately product sales occur outside united states currency fluctuations hedging expenses may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates us dollar strengthens foreign currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increases overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar use foreign currency exchange forward option contracts hedge percentage forecasted international sales primarily denominated euro also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid foreign currency exchange net hedges unfavorable impact product sales million year ended december compared period predict future fluctuations foreign currency exchange rates us dollar us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation results operations adversely affected stock price may decline additionally expenses recognize relation hedging activities also cause earnings fluctuate level hedging expenses recognize particular period impacted changes interest rate spreads foreign currencies hedge us dollar significant safety issues arise marketed products product candidates future sales may reduced would adversely affect results operations data supporting marketing approvals products forming basis safety warnings product labels obtained controlled clinical trials limited duration cases postapproval use products used longer periods time many patients underlying health problems taking numerous medicines expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings contraindications labels narrow approved indications could reduce market acceptance products regulatory authorities moving towards active transparent pharmacovigilance making greater amounts standalone safety information clinical trial data directly available public websites means periodic safety update report summaries risk management plan summaries various adverse event data safety information without appropriate context expertise may misinterpreted lead misperception legal action may potentially cause product sales stock price decline yescarta novel car cell therapy treatmentrelated adverse effects may appropriately recognized managed treating medical staff toxicities resulting personalized cell therapy typically encountered general patient population medical personnel common medicines may used academic medical centers hospitals help manage adverse side effects yescarta tocilizumab corticosteroids may available sufficient quantities may adequately control adverse side effects andor may detrimental impact efficacy treatment trained expect continue train medical personnel understand side effect profile yescarta compliance rems program required fda yescarta although give assurances efficacy training efforts inadequate training recognizing managing potential adverse effects yescarta disregard modification training medical staff could result severe prolonged toxicities even patient deaths serious safety resistance drug interaction issues arise marketed products sales products could limited halted us regulatory authorities results operations would adversely affected operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda european medicines agency ema comparable regulatory agencies countries continuing clinical trials many products currently approved additional uses anticipate file marketing approval additional countries additional indications products next several years products may fail receive marketing approvals timely basis manufacture sell products subject extensive regulation review discovery previously unknown problems marketed products problems manufacturing safety reporting promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements including related promotion manufacturing could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution example fda rules often required conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk implement rems products could include medication guide patient package insert communication plan healthcare providers elements fda deems necessary assure safe use drug could include imposing certain restrictions distribution use product failure comply requirements imposed fda could result significant civil monetary penalties operating results may adversely affected results anticipated timelines clinical trials uncertain may support continued development product candidate would adversely affect prospects future revenue growth required demonstrate safety efficacy products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products example terminated phase studies gs treatment rheumatoid arthritis cystic fibrosis phase study gs treatment hepatitis b virus determining study data showed insufficient evidence treatment benefit product candidates fails achieve primary endpoint clinical trials safety issues arise results clinical trials otherwise inadequate support regulatory approval product candidates commercialization product candidate could delayed halted addition may also face challenges clinical trial protocol design clinical trials product candidates pipeline delayed terminated prospects future revenue growth would adversely impacted example face numerous risks uncertainties product candidates including descovy preexposure prophylaxis prep selonsertib treatment nonalcoholic steatohepatitis nash andecaliximab treatment gastric cancer axicabtagene ciloleucel treatment second line diffuse large bcell lymphoma filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis currently phase clinical trials could prevent completion development product candidates risks include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain fda regulatory body approvals result product candidates may never successfully commercialized may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs others pipeline completed timely basis prospects future revenue growth may adversely impacted addition clinical trials involving commercial products could raise new safety issues existing products could turn decrease revenues harm business due reliance thirdparty contract research organizations conduct clinical trials unable directly control timing conduct expense quality clinical trials extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent third party contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management bioanalytical analysis many important aspects services performed us cros direct control dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals could adversely affected depend relationships companies sales marketing performance technology development logistics commercialization product candidates revenues failure maintain relationships poor performance companies disputes companies could negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance certain territories include collaborations janssen sciences ireland uc odefsey compleraeviplera symtuza europe bms atripla europe countries rely international distributors sales certain products relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline yescarta available rems program required fda mitigate potential risks product hospitals associated clinics certified rems program permitted dispense yescarta relevant staff involved prescribing dispensing administering yescarta must trained rems program requirements must successfully complete rems program knowledge assessment failure hospitals clinics enroll yescarta rems program successfully complete comply program requirements may result regulatory action fda decreased sales yescarta could harm business reputation yescarta rely technology partners assist development maintenance kite konnect platform platform critical ensure positive prescriber patient experience well chain identity chain custody yescarta technology platform incomplete insufficiently maintained develops technological issues may experience disruption sales logistics yescarta business could extend significant period time may need expend considerable resources time repair improve platform cooperation partners addition rely sites collect patient white blood cells known apheresis centers shippers couriers hospitals logistical collection patients white blood cells ultimate delivery yescarta patients disruption difficulties incurred vendors could result product loss regulatory action harm yescarta business reputation addition ensure apheresis center prepared ship cells manufacturing facilities plan conduct quality certifications apheresis center however apheresis centers may choose participate certification process may unable complete certification timely manner could delay restrain manufacturing commercialization efforts result sales yescarta may limited could harm results operations success depends significant degree ability defend patents intellectual property rights domestically internationally may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology patents proprietary rights important business success depends significant degree ability obtain patents licenses patent rights preserve trade secrets internal knowhow defend infringement efforts invalidate patents operate without infringing intellectual property others properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents patent applications confidential period time patent issued result may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate litigation interference proceedings determine right patent validity patent granted litigation interference proceedings unpredictable expensive could divert management attention operations even ultimately successful results operations may adversely affected events example tdf one active pharmaceutical ingredients stribild compleraeviplera atripla truvada main active pharmaceutical ingredient viread faces generic competition european union united states certain countries addition emtricitabine active pharmaceutical ingredient truvada faces generic competition european union truvada also faces generic competition european union certain countries outside united states letairis also expected face generic competition united states starting july entry generic products may lead market share price erosion negative impact business results operations addition patents covering ranolazine active ingredient ranexa instead discovered sustainedrelease formulation ranolazine would achieve therapeutic plasma levels obtained patents formulations characteristic plasma levels achieve yescarta composition matter patent expired european union european union united states patent applications pending related kites proprietary manufacturing processes may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions supplementary protection certificates countries generic manufacturers sought may continue seek fda approval market generic versions products abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug see description anda litigation note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report form k risk factor entitled litigation generic manufacturers increased expenses may continue reduce earnings unsuccessful lawsuits claims patents may narrowed invalidated generic versions products could launched prior patent expiry beginning success depends large part ability operate without infringing upon patents proprietary rights third parties infringe valid patents third parties may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license commercially reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned third parties parties may claim cover use sofosbuvir axicabtagene ciloleucel bictegravir see also description litigation regarding sofosbuvir axicabtagene ciloleucel bictegravir note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report risk factors entitled hcv products proven infringe patents third party may required pay significant monetary damages could adversely affect financial results beginning party successful establishing exclusive rights axicabtagene ciloleucel anticipated revenues earnings sale product could adversely affected beginning also aware us patent nos assigned us department health human services purports claim process protecting primate host infection immunodeficiency retrovirus administering combination emtricitabine tenofovir tdf prior exposure host immunodeficiency retrovirus contact us department health human services scope relevance patents explained believe patents valid patent office given relevant prior art physicians patients using claimed methods years centers disease control prevention filed applications patents furthermore also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets internal knowhow technological innovation otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions trade secrets internal knowhow technological innovation confidential information become known independently discovered competitors enter disputes ownership inventions business results operations could adversely affected hcv products proven infringe patents third party may required pay significant monetary damages could adversely affect financial results patents patent applications claim sofosbuvir sovaldi chemical entity metabolites fixeddose combinations ledipasvir sofosbuvir harvoni sofosbuvir velpatasvir epclusa sofosbuvir velpatasvir voxilaprevir vosevi aware patents patent applications owned third parties may future alleged parties cover use hcv products third parties obtain valid enforceable patents successfully prove infringement patents hcv products could required pay significant monetary damages current legal proceedings significance related sofosbuvir include litigation idenix pharmaceuticals inc idenix march european patent office epo granted idenix european patent patent corresponds patent day patent granted filed opposition epo seeking revoke patent opposition hearing held february epo ruled favor revoked patent idenix appealed see also description idenix litigation note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report litigation merck august merck contacted us requesting pay royalties sales sofosbuvir obtain license us patent patent us patent patent coowns ionis pharmaceuticals inc patents cover compounds include may relate sofosbuvir filed lawsuit august us district court northern district california seeking declaratory judgment merck patents invalid infringed patent prosecution merck amended patent application attempt cover compounds related sofosbuvir initially march jury determined established mercks patents invalid lack written description lack enablement awarded merck million damages however june court ruled favor defense unclean hands determined merck may recover damages us patents judge determined merck required pay attorneys fees due exceptional nature case july court issued decision setting amount attorney fees awarded gilead merck filed notices appeal cafc regarding courts decision defense unclean hands award attorneys fees appealed issue relating invalidity mercks patent cafc heard oral arguments february decision defense unclean hands reversed appeal mercks patent upheld may required pay damages royalty sales sofosbuvircontaining products following appeal event judge indicated determine amount royalty necessary conclusion appeal case litigation university minnesota university minnesota university obtained patent patent purports broadly cover nucleosides antiviral anticancer activity august university filed lawsuit us us district court district minnesota alleging commercialization sofosbuvircontaining products infringes patent believe patent invalid infringed continued commercialization sofosbuvir october court granted motion transfer case california also filed four petitions inter partes review uspto alleging asserted claims invalid anticipation obviousness petitions inter partes review filed initiative medicines access knowledge october received notice initiative medicines access knowledge imak submitted multiple petitions requesting inter partes review uspto patent trial appeal board ptab alleging certain patents associated sofosbuvir invalid either novel obvious strongly believe imaks petitions without merit sofosbuvir approved hcv drug kind novel obvious accordingly defend allegations ptab decides initiate one inter partes reviews decision would expected year later either party appeal ptabs decision cafc european patent claims february several parties filed oppositions epo requesting revocation one granted european patents covering sofosbuvir expires october epo upheld validity certain claims sofosbuvir patent anticipate challengers appeal decision favor patent appealed decision seeking restore original claims several original opposing parties also appealed requesting full revocation appeal process may take several years april several parties filed oppositions epo requesting revocation granted european patent relating sofosbuvir expires predict ultimate outcome intellectual property claims related hcv products spent continue spend significant resources defending claims unsuccessful lawsuits could required pay significant monetary damages could significant negative effect financial results party successful establishing exclusive rights axicabtagene ciloleucel anticipated revenues earnings sale product could adversely affected october acquired kite whollyowned subsidiary acquisition acquired axicabtagene ciloleucel car cell therapy october received approval fda axicabtagene ciloleucel known commercially yescarta patents patent applications claim axicabtagene ciloleucel chimeric dna segments third parties may may obtain rights patents allegedly could used prevent attempt prevent us commercializing axicabtagene ciloleucel require us obtain license order commercialize axicabtagene ciloleucel example aware juno therapeutics inc juno exclusively licensed patent patent issued sloan kettering cancer center september juno sloan kettering cancer center filed lawsuit kite us district court central district california alleging commercialization axicabtagene ciloleucel infringes patent october following fda approval yescarta juno filed second complaint alleging axicabtagene ciloleucel infringes patent juno subsequently moved dismiss september complaint maintained october complaint august kite filed petition inter partes review uspto alleging asserted claims patent invalid obvious december ptab determined claims patent invalid due obviousness february kite filed notice appeal cafc appeal currently pending predict ultimate outcome intellectual property claims related axicabtagene ciloleucel junos patent upheld valid juno successfully proves infringement patent axicabtagene ciloleucel could prevented selling yescarta unless able obtain license patent license may available commercially reasonable terms could adversely impact business results operations manufacturing problems including thirdparty manufacturers corporate partners could cause inventory shortages delay product shipments regulatory approvals may adversely affect results operations order generate revenue products must able produce sufficient quantities products satisfy demand many products result complex manufacturing processes manufacturing process pharmaceutical products also highly regulated regulators may shut manufacturing facilities believe comply regulations products either manufactured facilities thirdparty manufacturers corporate partners depend third parties perform manufacturing activities effectively timely basis majority solid dose products thirdparty manufacturers corporate partners subject good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda ema similar regulations effect jurisdictions thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval may writeoff costs manufacturing batch fails pass quality inspection meet regulatory approval addition thirdparty manufacturers corporate partners may able produce products one limited number facilities therefore limited manufacturing capacity certain products may able locate additional replacement facilities reasonable basis sales products could also adversely impacted reliance limited number facilities extent risks materialize affect performance obligations us financial results may adversely affected manufacturing operations subject routine inspections regulatory agencies unable remedy deficiencies cited fda inspections currently marketed products timing regulatory approval products development could adversely affected risk regulatory agencies countries marketing applications pending undertake similar additional reviews apply heightened standard review could delay regulatory approvals products countries approval product candidates delayed production marketed products interrupted anticipated revenues stock price would adversely affected limited experience managing cell engineering process processes may difficult expensive approaches taken current future competitors sure manufacturing processes employed us result engineered cells safe effective addition may encounter difficulties production particularly scaling validating initial production meet patient demand ensuring absence contamination problems could include difficulties production costs yields quality control including stability product quality assurance testing operator error shortages qualified personnel well compliance strictly enforced federal state foreign regulations contaminants discovered supply yescarta manufacturing facilities manufacturing facilities may need closed extended period time investigate remedy contamination could require substantial resources management attention assure stability issues relating manufacture yescarta occur future issues may remedied timely basis addition may fail manage logistics collecting shipping patient material manufacturing site shipping yescarta back patient logistical shipment delays problems caused us vendors factors control weather natural disasters could prevent delay delivery products product candidates patients additionally required maintain complex chain identity custody respect patient material material moves manufacturing facilities manufacturing process back patient failure maintain chain identity custody could result patient death loss product regulatory action could adverse effect us reputation stock price may able obtain materials supplies necessary conduct clinical trials manufacture sell products would limit ability generate revenues need access certain supplies products conduct clinical trials manufacture products unable purchase sufficient quantities materials find suitable alternate materials timely manner development efforts product candidates may delayed ability manufacture products would limited would limit ability generate revenues suppliers key components materials must named new drug application maa filed fda ema regulatory authority product candidate seeking marketing approval significant delays occur qualification new supplier required even manufacturer qualified regulatory authority manufacturer must continue expend time money effort area production quality control ensure full compliance gmp manufacturers subject regular periodic inspections regulatory authorities following initial approval result inspections regulatory authority determines equipment facilities laboratories processes comply applicable regulations conditions product approval regulatory authority may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand would turn decrease revenues harm business addition delivery material suppliers interrupted reason may unable ship certain products commercial supply supply products development clinical trials addition products materials utilize operations made one facility may able replace timely manner commercially reasonable terms problems single suppliers depend including event disaster including earthquake equipment failure difficulty may negatively impact development commercialization efforts significant portion raw materials intermediates used manufacture antiviral products supplied thirdparty manufacturers corporate partners outside united states result political economic factors specific country region including changes interpretations trade regulations compliance requirements tax legislation would limit prevent third parties outside united states supplying materials would adversely affect ability manufacture supply antiviral products meet market needs material adverse effect operating results encounter difficulties ability provide products product candidates patients would jeopardized litigation generic manufacturers increased expenses may continue reduce earnings unsuccessful lawsuits claims patents may narrowed invalidated generic versions products could launched prior patent expiry part approval process products fda granted us new chemical entity nce exclusivity period manufacturers applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug anda application form typically used manufacturers seeking approval generic drug seek approval generic version product nce status generic manufacturer may submit anda fda four years branded products approval sofosbuvir date falls december consequently possible one generic manufacturers file anda sofosbuvir december current legal proceedings significance generic manufacturers include mylan february received notice mylan pharmaceuticals inc mylan submitted anda fda requesting permission manufacture market generic version tybost cobicistat notice mylan alleges patent covering cobicistat invalid obvious mylans generic product infringe invalid claim march filed lawsuits mylan us district court district delaware us district court northern district west virginia parties agreed dismiss action west virginia trial delaware stayed patent suit covers tybost also listed orange book stribild genvoya november received notice mylan submitted anda fda requesting permission manufacture market generic version evotaz atazanavircobicistat challenging validity cobicistat compound patent citing arguments made ongoing litigation involving tybost december filed lawsuit mylan us district court northern district west virginia amneal may received notice amneal pharmaceuticals llc amneal submitted anda fda requesting permission manufacture market generic version truvada low dosage strengths notice amneal alleges two patents associated emtricitabine invalid unenforceable andor infringed amneals manufacture use sale generic versions truvada low dosage strengths july filed lawsuit amneal us district court district delaware infringement patents natco teva february received notices natco pharma limited natco teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version sovaldi tevas notice alleges nine patents associated sofosbuvir invalid unenforceable andor infringed tevas manufacture use sale generic versions sovaldi natcos notice alleges two patents associated sofosbuvir invalid unenforceable andor infringed natcos manufacture use sale generic versions sovaldi natco challenge patents listed orange book sovaldi evaluating notice letters determining next steps predict ultimate outcome foregoing actions litigation generic manufacturers may spend significant resources enforcing defending patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection products could substantially shortened patents covering one products invalidated fda could approve requests manufacture generic version products united states prior expiration date patents sale generic versions products earlier patent expiration would significant negative effect revenues results operations imports countries products available lower prices unapproved generic counterfeit versions products could negative impact reputation business prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets hiv hbv hcv products agreed make available substantially reduced prices certain low middleincome countries participating gilead access program exported low middleincome countries united states europe higher price markets revenues would adversely affected addition entered voluntary licensing agreements generic drug companies india south africa china well licensing agreement medicines patent pool united nationsbacked public health organization allows generic drug companies manufacture generic versions hiv hbv products incorporating licensed compounds taf cobicistat elvitegravir bictegravir distribution certain low middleincome countries also entered licensing agreements generic manufacturers india egypt pakistan produce distribute generic versions hcv products certain low middleincome countries generic versions hiv hbv hcv products licenses reexported united states europe markets outside low middleincome countries revenues would adversely affected addition purchases products countries selling prices relatively low resale countries selling prices relatively high may adversely impact revenues gross margin may cause sales fluctuate quarter quarter example european union required permit products purchased one country sold another country purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter quarterly fluctuations may impact earnings could adversely affect stock price harm business also aware existence various buyers clubs around world promote personal importation generic versions hcv products approved use countries imported result patients may risk taking unapproved medications may purport may potency claim may contain harmful substances extent patients take unapproved generic versions one medications injured cured products brand commercial scientific reputation hcv products could harmed third parties may illegally distribute sell counterfeit versions products meet rigorous quality standards manufacturing supply chain example first quarter bottles counterfeit drugs labeled harvoni brand name discovered retail pharmacy chain pharmaceutical wholesalers japan investigated matter accelerated planned changes product packaging make counterfeiting difficult cooperated continue cooperate japanese health ministry also third quarter bottles counterfeit drugs labeled sovaldi brand name discovered retail pharmacy chain pharmaceutical wholesalers germany investigated matter determined number wholesalers obtained sovaldi unapproved source cooperated continue cooperate german regulatory authorities also reports product labeled epclusa available multiple countries determined authentic product based sample analysis lot number working regulatory authorities investigate matter actively take actions discourage counterfeits products around world including working local regulatory legal authorities enforce laws counterfeit drugs counterfeit drugs pose serious risk patient health safety reputation business could suffer result counterfeit drugs sold brand name expensive litigation government investigations increased expenses may continue reduce earnings involved number litigation investigation disputerelated matters require us expend substantial internal financial resources expect matters continue require high level internal financial resources foreseeable future matters reduced continue reduce earnings require significant management attention please see description litigation investigation disputerelated matters note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report outcome legal proceedings legal proceedings may brought us investigations investigations may initiated disputerelated matters inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us could significantly reduce earnings cash flows harm business countries may required grant compulsory licenses products patents may enforced number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv hcv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example growing attention availability hcv therapies activists advocating increased availability hcv therapies means including compulsory licenses government malaysia exercised government rights section malaysian patents act practice patented invention sofosbuvir period three years use government hospitals clinics challenging malaysian governments actions past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread compulsory licenses permit generic manufacturing override product patents hiv hcv products required grant compulsory licenses products could reduce earnings cash flows harm business addition certain countries permit enforcement patents permit patents issue thirdparty manufacturers able sell generic versions products countries example brazilian health regulatory agency rejected patent applications related sofosbuvir hcv products successfully appealed decisions applications examination brazilian patent trademark office sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales may face significant liability resulting products may covered insurance liability could materially reduce earnings testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others may sufficient insurance coverage product liabilities may arise addition cost defend lawsuits pay damages product liability claims may exceed insurance coverage maintain adequate coverage claims exceed coverage financial condition adversely affected addition negative publicity associated claims regardless merit may decrease future demand products impair financial condition business disruptions natural manmade disasters may harm future revenues worldwide operations could subject business interruptions stemming natural manmade disasters may uninsured inadequately insured corporate headquarters foster city santa monica location together house majority rd activities san dimas la verne oceanside el segundo manufacturing facilities located california seismically active region may carry adequate earthquake insurance significant recovery time could required resume operations financial condition operating results could materially adversely affected event major earthquake addition yescarta business also reliant ability manage logistics collecting shipping patient material manufacturing facilities shipping yescarta back patient logistical shipment delays caused natural manmade disasters could prevent delay delivery products patients could harm yescarta business dependent information technology systems infrastructure data dependent upon information technology systems infrastructure data including new kite konnect platform multitude complexity computer systems make inherently vulnerable service interruption destruction malicious intrusion random attack likewise data privacy security breaches employees others may pose risk sensitive data including intellectual property trade secrets personal information employees patients customers business partners may exposed unauthorized persons public cyberattacks increasing frequency sophistication intensity cyberattacks could include deployment harmful malware denialofservice social engineering means affect service reliability threaten data confidentiality integrity availability business technology partners face similar risks security breach systems could adversely affect security posture invested continue invest protection data information technology infrastructure assurance efforts efforts partners vendors prevent service interruptions identify breaches systems could adversely affect business operations andor result loss critical sensitive information could result financial legal business reputational harm us addition liability insurance may sufficient type amount cover us claims related security breaches cyberattacks related breaches regulators globally also imposing greater monetary fines privacy violations example european union adopted new law governing data practices privacy called general data protection regulation gdpr becomes effective may law establishes new requirements regarding handling personal data noncompliance gdpr may result monetary penalties worldwide revenue gdpr changes laws regulations associated enhanced protection certain types sensitive data healthcare data personal information could greatly increase cost providing products services even prevent us offering certain services jurisdictions operate changes effective income tax rate could reduce earnings subject income taxes united states various foreign jurisdictions including ireland due economic political conditions various countries actively considering made changes existing tax laws predict form timing potential legislative changes could material adverse impact results operations example united states recently enacted significant tax reform certain provisions new law significantly affect us accounting changes currently considered provisional may change materially measurement period due issuance anticipated guidance finalization certain accounting method elections see note income taxes notes consolidated financial statements included part ii item annual report additional details addition significant judgment required determining worldwide provision income taxes various factors may favorable unfavorable effects income tax rate including limited changes forecasted demand hcv products portion nontax deductible annual bpd fee accounting stock options sharebased awards mergers acquisitions ability manufacture product cork ireland facility amortization certain acquisition related intangibles receive tax benefit future levels rd spending changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact consolidated results operations income tax returns subject audit federal state foreign tax authorities currently examination internal revenue service tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions resolution one exposures reporting period could material impact results operations period fail attract retain highly qualified personnel may unable successfully develop new product candidates conduct clinical trials commercialize product candidates future success depend large part continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization face competition personnel companies universities public private research institutions government entities organizations competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit may able attract retain quality personnel acceptable terms additionally changes us immigration work authorization laws regulations could make difficult employees work transfer jurisdictions operations could impair ability attract retain qualified personnel unsuccessful recruitment retention efforts business may harmed assurance pay dividends continue repurchase stock board directors authorized dividend program intend pay quarterly dividends per share subject quarterly declarations board directors board directors also approved repurchase billion common stock billion available repurchase december future declarations amount timing dividends andor amount timing stock repurchases subject capital availability determinations board directors cash dividends andor stock repurchases best interest stockholders compliance respective laws agreements applicable declaration payment cash dividends repurchase stock ability pay dividends andor repurchase stock depend upon among factors cash balances potential future capital requirements strategic transactions including acquisitions debt service requirements results operations financial condition factors beyond control board directors may deem relevant reduction elimination dividend payments dividend program andor stock repurchases could negative effect stock price item b unresolved staff comments applicable item properties corporate headquarters located foster city california house administrative manufacturing rd activities also rd facilities oceanside santa monica california seattle washington alberta canada manufacturing facilities el segundo la verne oceanside san dimas california alberta canada cork ireland global operations include offices europe north america asia south america africa australia middle east believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings description significant pending legal proceedings please see note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report incorporated herein reference item mine safety disclosures applicable part ii item market registrants common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild following table sets forth high low intraday sale prices per share common stock nasdaq global select market periods indicated prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low high low first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record include shares held broker bank nominee dividends declared paid quarterly cash dividends aggregate amount billion per common share declared paid quarterly cash dividends aggregate amount billion per common share see note stockholders equity notes consolidated financial statements included item annual report additional information performance graph following graph compares cumulative total stockholder return past five years two indices standard poors stock index labeled sp index nasdaq biotechnology index labeled nbi index stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years notes section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december dividends reinvested issuer purchases equity securities first quarter board directors authorized billion share repurchase program program repurchases may made open market privately negotiated transactions started repurchases program april repurchased retired million shares common stock million open market transactions program table summarizes stock repurchase activity three months ended december maximum fair total number value shares total number average shares purchased may yet shares price paid part publicly purchased purchased per share announced program program thousands dollars thousands millions october october november november december december total note difference total number shares purchased total number shares purchased part publicly announced program due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations item selected financial data gilead sciences inc selected consolidated financial data millions except per share data year ended december consolidated statement income data total revenues total costs expenses income operations provision income taxes net income net income attributable gilead net income per share attributable gilead common stockholders basic shares used per share calculation basic net income per share attributable gilead common stockholders diluted shares used per share calculation diluted cash dividends declared per share december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations longterm debt including current portion retained earnings total stockholders equity notes see managements discussion analysis financial condition results operations included item annual report description results operations december recorded estimated billion net charge related enactment tax cuts jobs act see note income taxes notes consolidated financial statements included item annual report additional details connection acquisition kite pharma inc issued billion aggregate principal amount senior unsecured notes registered offering drew billion aggregate principal amount term loan facility credit agreement billion repaid december issued billion principal amount senior unsecured notes registered offering also repaid million principal balance convertible senior notes due may million principal balance senior unsecured notes due december issued billion principal amount senior unsecured notes registered offering also repaid million principal balance convertible senior notes due may issued billion principal amount senior unsecured notes registered offerings also repaid million principal balance convertible senior notes due may million principal balance senior unsecured notes due december million fiveyear revolving credit facility agreement repaid billion principal balance convertible senior notes repaid million fiveyear revolving credit facility agreement retrospectively adopted accounting standards update balance sheet classification deferred taxes requires deferred tax assets liabilities classified noncurrent balance sheet result reclassified deferred tax assets total current assets longterm assets deferred tax liabilities accrued liabilities longterm obligations years presented retrospectively adopted accounting standards update simplifying presentation debt issuance costs requires presentation debt issuance costs direct deduction carrying amount recognized debt liability balance sheet result reclassified unamortized debt issuance costs assets long term debt including current portion years presented item managements discussion analysis financial condition results operations following managements discussion analysis financial condition results operations mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report including disclosures part item risk factors consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars management overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world operations countries worldwide headquarters foster city california gileads primary areas focus include hivaids liver diseases hematologyoncology inflammationrespiratory diseases seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategies portfolio marketed products includes ambisome atripla biktarvy cayston compleraeviplera descovy emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada tybost vemlidy viread vosevi yescartatm zydelig us international commercial sales operations marketing subsidiaries countries also sell distribute certain products corporate partners royaltypaying collaborative agreements business highlights marked operational excellence across business accomplished many key goals position us future growth observed strong performance hiv cardiovascular products continued execute maximize opportunity hcv changing competitive landscape addition continued advance product pipeline across therapeutic areas goal delivering bestinclass drugs advance current standard care andor address unmet medical need recent key developments include key announcements fda granted priority review new drug application nda biktarvy fixeddose combination bictegravir bic novel investigational integrase strand transfer inhibitor emtricitabinetenofovir alafenamide taf treatment hiv infection addition marketing authorization application biktarvy fully validated evaluation european medicines agency ema received us food drug administration fda approval biktarvy february european commission granted marketing authorization vemlidy oncedaily tablet treatment chronic hepatitis b virus hbv infection adults adolescents aged years older body weight least kg european commission fda approved vosevi oncedaily single tablet regimen treatment hcv infection adults genotype vosevi first single tablet regimen patients previously failed therapy directacting antiviral daa treatments latest regimen portfolio sofosbuvirbased hcv daa treatments announced new licensing agreement medicines patent pool mpp united nationsbacked public health organization expand access bic agreement mpp sublicense rights bic generic drug companies india china south africa manufacture therapies containing bic distribution certain low middleincome countries china food drug administration approved sovaldi treatment hcv infection sovaldi approved treatment adults adolescents aged years infected hcv genotypes component combination antiviral treatment regimen sovaldi first hcv medicine approved china fda approved expanded labeling epclusa first alloral pangenotypic oncedaily single tablet regimen treatment adults hcv infection include use patients coinfected hiv european commission extended marketing authorization harvoni include treatment hcv infection adolescents infected genotype harvoni first daa regimen receive marketing authorization european union extended use adolescent population fda approved supplemental indications harvoni sovaldi treatment hcv infection adolescents without cirrhosis compensated cirrhosis years age older weighing least kilograms harvoni approved pediatric patients genotype hcv infection sovaldi approved pediatric patients genotype hcv infection combination ribavirin acquisitions october completed tender offer outstanding common stock kite pharma inc kite per share cash approximately billion excluding approximately billion relating portion replaced stockbased awards attributable post combination period financed transaction billion aggregate principal amount senior unsecured notes issued september billion aggregate principal amount term loan facility credit agreement entered september drawn october billion repaid december well cash hand kites cell therapies express either chimeric antigen receptor car engineered cell receptor depending type cancer acquisition resulted kite becoming whollyowned subsidiary established us leader cellular therapy kite acquisition acquired axicabtagene ciloleucel car cell therapy october received approval fda axicabtagene ciloleucel known commercially yescarta making first car cell therapy treatment adult patients relapsed refractory large b cell lymphoma two lines systemic therapy includes diffuse large bcell lymphoma transformed follicular lymphoma primary mediastinal bcell lymphoma also filed marketing authorization application axicabtagene ciloleucel treatment indications ema representing first known submission europe car cell therapy approval europe expected first half although assurance receive approval timely basis addition axicabtagene ciloleucel also acquired therapy candidates clinical trials hematologic cancers solid tumors including kite car cell therapy candidate targets bcell maturation antigen expressed multiple myeloma december acquired issued outstanding stock cell design labs inc cell design labs privately held company addition approximately shares cell design labs obtained acquisition kite acquisition gained new technology platforms enhance research development efforts cellular therapy see note acquisitions notes consolidated financial statements included item annual report additional information regarding acquisition kite cell design labs financial highlights total revenues decreased billion total product sales decreased billion compared billion billion respectively primarily due competitive dynamics hcv market lowered sales hcv products partially offset higher sales hiv products united states product sales billion compared billion europe product sales billion compared billion sales international locations billion compared billion research development rd expenses decreased billion compared primarily due impacts business development activities resulting upfront collaboration expense related license collaboration agreement galapagos nv galapagos acquired process rd iprd expense related purchase nimbus apollo inc nimbus iprd impairment charges ongoing milestone payments partially offset acquired iprd expense related purchase cell design labs selling general administrative sga expenses increased billion compared primarily due costs associated acquisition kite higher branded drug prescription bpd fee expense provision income taxes increased billion compared billion primarily due estimated billion net charge related enactment tax cuts jobs act tax reform fourth quarter net income attributable gilead billion per diluted share compared billion per diluted share primarily due lower product sales impact tax reform december billion cash cash equivalents marketable securities compared billion december generated billion operating cash flow paid cash dividends billion repurchased total million shares million open market transactions outlook continue maintain strong focus operational excellence financial discipline rd perspective continue invest new ongoing clinical studies support existing products product candidates expect move forward number clinical studies new product candidates including advancing cell therapy pipeline continuing progression phase studies selonsertib nonalcoholic steatohepatitis nash filgotinib rheumatoid arthritis inflammatory bowel disease order develop product pipeline focus leveraging balance sheet pursue partnering acquisition opportunities fit longterm strategic plan commercial perspective support launch biktarvy continue promote use existing tafcontaining regimens addition believe truvada preexposure prophylaxis prep continue integral part growth hiv united states communities embrace public health benefits prevention hcv expect decline product sales major markets result increased competition hcv revenues driven four variables patient starts net pricing market share treatment duration treatment duration stabilized variable pricing regimens gravitated towards week regimen price anticipate pricing market share stabilize mid predictable slightly declining patient starts moving forward cell therapy continue promote use yescarta united states prepare anticipated approval europe continue help ensure patient access products around world including gilead access program million people receive hiv medicines low middleincome countries progress initiatives subject number uncertainties including limited continuation uncertain global macroeconomic environment additional pricing pressures payers competitors slower anticipated growth hiv products increase discounts chargebacks rebates due ongoing contracts future negotiations commercial government payers market share price erosion caused introduction generic versions truvada outside united states viread letairis united states inaccuracies hcv patient start estimates potential amendments affordable care act government action could effect lowering prices larger anticipated shift payer mix highly discounted payer segment volatility foreign currency exchange rates results operations total revenues following table summarizes period period changes product sales royalty contract revenues millions except percentages change change revenues product sales royalty contract revenues total revenues product sales compared total product sales billion compared billion primarily due decrease antiviral product sales antiviral product sales include sales hiv hbv hcv products billion compared billion hiv hbv product sales billion compared billion increase primarily driven continued uptake tafbased products partially offset decreases sales tenofovir disoproxil tdfbased products hcv product sales consist harvoni epclusa sovaldi vosevi billion compared billion declines hcv product sales across major markets result increased competition lower total market patient starts product sales include sales letairis ranexa ambisome billion increase compared billion letairis expected face generic competition united states starting july product sales generated outside united states faced exposure movements foreign currency exchange rates primarily euro used foreign currency exchange contracts hedge percentage foreign currency exposure foreign currency exchange net hedges unfavorable impact million product sales compared record product sales net estimated mandatory supplemental discounts government payers addition discounts private payers including rebates chargebacks cash discounts prompt payment distributor fees related costs deductions generally referred grossto net deductions totaled billion gross product sales compared billion billion billion gross product sales related government rebates chargebacks billion related cash discounts prompt payment distributor fees related costs product sales united states decreased billion compared billion declines sales hcv products partially offset increases sales hiv hbv products declines sales hcv products primarily due lower harvoni sovaldi sales volume result increased competition lower total market patient starts additionally increases epclusa vosevi sales volume partially offset lower average net selling price epclusa pricing regimens gravitated towards week regimen price increases sales hiv hbv products primarily driven higher sales volume tafbased products higher average net selling prices partially offset decreases tdf based products prior year impact favorable revision rebate reserves million primarily related tdfbased products product sales europe decreased billion compared billion primarily due lower harvoni sovaldi sales volume partially offset higher epclusa sales volume foreign currency exchange net hedges unfavorable impact million product sales compared product sales international locations decreased billion compared billion primarily due lower sales japan sales hcv products japan million compared billion period primarily due lower sales volume result lower total market patient starts increased competition compared total product sales billion compared billion primarily due decrease antiviral product sales antiviral product sales billion compared billion hiv hbv product sales billion compared billion increase primarily driven continued uptake tafbased products partially offset decreases sales tdfbased products hcv product sales billion compared billion declines due lower sales harvoni sovaldi partially offset sales epclusa launched across various locations product sales include sales letairis ranexa ambisome billion increase compared billion product sales generated outside united states foreign currency exchange net hedges unfavorable impact million product sales compared grosstonet deductions totaled billion gross product sales compared billion billion billion gross product sales related government rebates chargebacks billion related cash discounts prompt payment distributor fees related costs increase grosstonet deductions primarily due increase discounts higher percentage sales deeply discounted segments hcv products united states product sales united states decreased billion compared billion declines sales hcv products partially offset increases sales hiv hbv products increases sales hiv hbv products primarily driven sales newly launched tafbased products favorable revision rebate reserves million primarily related tdfbased products product sales europe decreased billion compared billion primarily due lower harvoni sovaldi sales volume foreign currency exchange net hedges unfavorable impact million product sales compared product sales international locations increased billion compared billion primarily due sales japan sales hcv products japan billion compared billion increase primarily driven higher sales volume harvoni launched september partially offset mandatory price reduction sovaldi harvoni effective april following table summarizes period period changes product sales millions except percentages change change antiviral products hcv products harvoni epclusa sovaldi vosevi hiv hbv products genvoya truvada atripla descovy odefsey stribild viread compleraeviplera total antiviral products products letairis ranexa ambisome zydelig total product sales percentage meaningful following additional discussion results product harvoni harvoni sales accounted total antiviral product sales respectively product sales billion united states million europe million international locations product sales billion united states billion europe billion international locations product sales billion united states billion europe billion international locations decreases compared major markets primarily due lower sales volume united states decrease compared primarily due lower sales volume lower average net selling price partially offset favorable revision sales return reserve million recorded second quarter number patients started treatment harvoni united states peaked first half many warehoused patients initiated treatment product launch europe decrease compared primarily due lower sales volume unfavorable foreign currency exchange net hedges international locations increase compared primarily due higher sales japan sales japan billion compared billion driven higher sales volume partially offset mandatory price reduction effective april epclusa epclusa approved fda european commission june july respectively epclusa sales accounted total antiviral product sales respectively product sales billion united states million europe million international locations product sales billion united states million europe million international locations increases compared major markets primarily due higher sales volume partially offset decrease average net selling price sovaldi sovaldi sales accounted total antiviral product sales respectively product sales million united states million europe million international locations product sales billion united states million europe billion international locations product sales billion united states billion europe billion international locations decreases compared major markets primarily due lower sales volume driven shift market sovaldi epclusa united states decrease compared primarily due lower sales volume partially offset favorable revision sales return reserve million recorded second quarter europe decrease compared primarily due lower sales volume international locations slight decrease primarily due lower sales japan sales japan million compared million due mandatory price reduction effective april lower sales volume tafbased regimens genvoya descovy odefsey genvoya approved fda european commission november descovy approved fda european commission april odefsey approved fda european commission march june respectively product sales tafbased regimens billion billion million respectively accounted total antiviral product sales respectively product sales billion united states million europe million international locations product sales billion united states million europe million international locations increases compared major markets primarily driven higher sales volume patients shifted away tdfbased regimens europe product sales tafbased regimens continue grow despite availability generic viread truvada several countries tdfbased regimens stribild compleraeviplera atripla truvada viread product sales tdfbased regimens billion billion billion respectively accounted total antiviral product sales respectively product sales billion united states billion europe million international locations product sales billion united states billion europe million international locations product sales billion united states billion europe million international locations united states decreases compared primarily due lower sales volume result continued uptake taf based regimens partially offset increased usage truvada prep europe decreases compared primarily due lower sales volume result availability generic viread truvada several countries continued uptake tafbased regimens united states increases compared primarily due favorable revision rebate reserves million relating stribild complera third quarter europe decreases compared primarily due lower sales volume result continued uptake tafbased regimens royalty contract revenues following table summarizes period period changes royalty contract revenues millions except percentages change change royalty contract revenues royalty contract revenues slightly compared period decreased compared million decrease compared primarily due royalty revenues f hoffmanla roche ltd sales tamiflu cost goods sold product gross margin following table summarizes period period changes product sales cost goods sold product gross margin millions except percentages change change total product sales cost goods sold product gross margin decreases product gross margin compared compared primarily due changes product mix hcv product sales decreased percentage total product sales research development expenses following table summarizes period period changes rd expenses millions except percentages change change rd expenses rd expenses summarized consisted primarily clinical studies performed contract research organizations materials supplies licenses fees upfront payments collaboration agreements milestone payments personnel costs including salaries benefits stockbased compensation overhead allocations consisting various support facilitiesrelated costs track total rd expenses product candidate therapeutic area development phase however manage rd expenses identifying rd activities anticipate performed given period prioritizing efforts based scientific data probability successful development market potential available human capital resources considerations continually review rd pipeline status development necessary reallocate resources among rd portfolio believe best support future growth business following table provides breakout rd expenses major cost type millions except percentages clinical studies outside services personnel infrastructure expenses facilities costs iprd impairment charges acquired iprd upfront collaboration expenses total rd expenses decreased billion compared primarily due impacts business development activities resulting front collaboration expense related license collaboration agreement galapagos acquired iprd expense related purchase nimbus iprd impairment charges ongoing milestone payments partially offset acquired iprd expense related purchase cell design labs rd expenses increased billion compared primarily due overall progression clinical studies including ongoing milestone payments purchase fda priority review voucher upfront collaboration expenses related license collaboration agreement galapagos acquired iprd expense related purchase nimbus iprd impairment charges result termination clinical development momelotinib simtuzumab selling general administrative expenses following table summarizes period period changes sga expenses millions except percentages change change sga expenses sga expenses relate sales marketing finance human resources legal administrative activities expenses consist primarily personnel costs facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses also include bpd fee united states along pharmaceutical manufacturers branded drug products required pay portion bpd fee estimated based select government sales calendar year percentage total industry government sales truedup upon receipt invoices internal revenue service irs sga expenses increased million compared primarily due costs associated acquisition kite primarily consist stockbased compensation transaction costs well higher bpd fee expenses resulting favorable adjustment million first quarter sga expenses flat compared declines bpd fee expenses offset higher costs support new product launches geographic expansion bpd fee expenses favorably impacted credit million based receipt irs invoice bpd fee expenses million million million bpd fee expenses tax deductible interest expense interest expense increased billion compared million primarily due issuance billion aggregate principal amount senior unsecured notes september notes interest expense increased million compared million primarily due issuance notes billion aggregate principal amount senior unsecured notes issued september income expense net income expense net million million million respectively increases primarily due cash cash equivalents marketable securities earning higher yield higher cash balances provision income taxes provision income taxes billion compared billion effective tax rate increased effective tax rate primarily due enactment tax reform december changes geographic mix earnings also contributed increase effective tax rate december tax reform signed law united states making significant changes internal revenue code amended changes include limited corporate tax rate decrease effective tax years beginning december implementation modified territorial tax system repatriation tax deemed repatriated earnings foreign subsidiaries calculated provisional estimate impact tax reform income tax provision accordance interpretation tax reform guidance available date filing result recorded estimated billion net charge income tax expense fourth quarter period tax reform enacted amount includes provisional million deferred tax benefit related remeasurement certain deferred tax assets liabilities based revised rates expected reverse future ii provisional billion charge related transition tax mandatory deemed repatriation accumulated foreign earnings determined december provisional transition tax charge includes federal net certain offsetting adjustments related unrecognized tax benefits state local foreign withholding tax accumulated foreign earnings longer considered indefinitely reinvested december accrued federal liability transition tax billion payable eight year period december million transition tax recorded within accrued liabilities billion recorded longterm income taxes payable consolidated balance sheets accordance us securities exchange commission sec staff accounting bulletin sab determined million deferred tax benefit recorded connection remeasurement certain deferred tax assets liabilities billion current tax expense recorded connection transition tax mandatory deemed repatriation foreign earnings provisional subject adjustment measurement period exceed one year enactment tax reform given complexity tax reform may refining estimates provisional amounts guidance issued us treasury sec financial accounting standards board fasb additionally continuing evaluate accounting policy election required regard tax global intangible lowtaxed income global minimum tax fasb allows companies adopt policy election account global minimum tax one two methods account global minimum tax component tax expense period company subject rules period cost method ii account global minimum tax companys measurement deferred taxes deferred method elected method completion analysis global minimum tax provisions election method depend part analyzing expected future us taxable income inclusions related global minimum tax methodologies order determine appropriate method decide elect deferred method accounting global minimum tax possible provisional estimate remeasuring deferred taxes may materially change finalize analysis accounting policy election measurement period provision income taxes billion effective tax rate increased primarily due changes geographic mix earnings liquidity capital resources believe existing capital resources supplemented cash flows generated operating activities adequate satisfy capital needs foreseeable future following table summarizes cash cash equivalents marketable securities working capital millions december cash cash equivalents marketable securities working capital cash cash equivalents marketable securities cash cash equivalents marketable securities totaled billion december increase billion compared billion december generated billion operating cash flow connection acquisition kite issued billion aggregate principal amount senior unsecured notes entered drew billion aggregate principal amount term loan facility credit agreement billion repaid december additionally paid cash dividends billion utilized million stock repurchases see note acquisitions notes consolidated financial statements included item annual report additional details acquisition kite cash cash equivalents marketable securities totaled billion december increase billion compared billion december generated billion operating cash flow received billion net proceeds notes utilized billion repurchase stock repaid million principal balance senior notes convertible senior notes paid cash dividends billion total cash cash equivalents marketable securities december approximately billion generated operations foreign jurisdictions february repatriated billion cash cash equivalents marketable securities parent company headquartered united states prior enactment tax reform earnings considered indefinitely reinvested us taxes provided us taxes provided earnings accrual tax reform transition tax see note income taxes notes consolidated financial statements included item annual report additional details tax reform working capital working capital billion december increase billion working capital december primarily driven increase cash cash equivalents shortterm marketable securities resulting shift duration marketable securities portfolio reduce interest rate risk partially offset billion increase current portion longterm debt based contractual maturity working capital billion december decrease billion working capital december primarily due decline cash cash equivalents result increase longterm marketable securities cash flows following table summarizes cash flow activities millions cash provided used operating activities investing activities financing activities cash provided operating activities cash provided operating activities represents cash receipts disbursements related activities investing financing activities operating cash flow derived adjusting net income noncash items changes operating assets liabilities cash provided operating activities decreased billion billion compared primarily due lower cash receipts result lower product sales higher tax payments cash provided operating activities decreased billion billion compared primarily due lower cash receipts result lower product sales higher cash payments related accrued government rebates chargebacks cash used investing activities cash used investing activities primarily consists acquisitions net cash acquired net purchases marketable securities investments capital expenditures cash used investing activities increased billion billion compared primarily due acquisition kite partially offset lower net purchases marketable securities cash used investing activities decreased million billion compared primarily due lower net purchases marketable securities partially offset investments related license collaboration agreement galapagos cash provided used financing activities cash provided financing activities billion compared cash used financing activities billion primarily due lower repurchases common stock higher proceeds issuances debt partially fund acquisition kite cash used financing activities increased billion billion compared primarily due higher repurchases common stock higher net payments debt higher payments cash dividends lower proceeds issuances debt increases partially offset lower payments settle warrants related convertible senior notes due may debt credit facilities longterm obligations summary borrowings various financing arrangements included note debt credit facilities notes consolidated financial statements included item annual report senior unsecured notes connection acquisition kite issued billion aggregate principal amount senior unsecured notes consisting million principal amount floating rate notes due september million principal amount floating rate notes due march million principal amount floating rate notes due september collectively floating rate notes billion principal amount senior notes due september fixed rate notes collectively floating rate notes notes floating rate notes bear interest rates equal three month london interbank offered rates libor plus respect floating rate notes due september respect floating rate notes due march respect floating rate notes due september fixed rate notes pay interest semiannually floating rate notes pay interest quarterly september issued notes aggregate principal amount billion december repaid million principal balance related senior unsecured notes required comply certain covenants notes indentures december violation covenants term loan facilities september entered billion aggregate principal amount term loan facility credit agreement consisting billion principal amount day senior unsecured term loan facility billion principal amount threeyear senior unsecured term loan facility billion principal amount fiveyear senior unsecured term loan facility collectively term loan facilities october drew billion aggregate principal amount term loan facilities used proceeds finance acquisition kite term loan facilities bear interest floating rates based libor plus applicable margin vary based debt ratings fitch ratings inc moodys investors service inc sp global ratings day senior unsecured term loan facility threeyear senior unsecured term loan facility due payable maturity fiveyear senior unsecured term loan facility payable quarterly amounts equal initial principal amount fiveyear senior unsecured term loan facility fiscal quarter end date second anniversary closing date remaining balance due payable maturity may prepay loans term loan facilities whole part time without premium penalty amounts repaid term loan facilities reborrowed term loan facilities contain customary representations warranties affirmative negative financial maintenance covenants events default december violation covenants repaid billion principal balance related threeyear senior unsecured term loan facility million term loan facility issued may credit facilities terminated fiveyear billion revolving credit facility entered billion fiveyear revolving credit facility maturing may fiveyear revolving credit agreement revolving credit facility used working capital requirements general corporate purposes including without limitation acquisitions required comply certain covenants fiveyear revolving credit agreement december violation covenants amounts outstanding fiveyear revolving credit agreement capital return program stock repurchase programs first quarter board directors authorized billion stock repurchase program program repurchases may made open market privately negotiated transactions program commenced billion stock repurchase program authorized board directors january completed second quarter billion stock repurchase program authorized board directors may completed first quarter december remaining authorized repurchase amount program billion following table summarizes stock repurchases abovedescribed programs millions year ended december shares repurchased retired amount notes repurchases program includes million shares repurchased billion program million shares repurchased billion program includes million shares repurchased billion program million shares repurchased billion program dividends february announced board directors declared quarterly cash dividend per share common stock payment date march stockholders record close business march future dividends subject declaration board directors declared paid quarterly cash dividends aggregate amount billion per common share declared paid quarterly cash dividends aggregate amount billion per common share see note stockholders equity notes consolidated financial statements included item annual report additional information capital resources believe existing capital resources supplemented cash flows generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products debt service requirements establishment additional collaborative relationships companies costs associated defense settlement adverse results government investigations litigation including matters related sofosbuvir may future require additional funding could form proceeds equity debt financings funding required guarantee available us favorable terms entered collaboration arrangement bristolmyers squibb company bms develop commercialize single tablet regimen containing truvada bmss sustiva efavirenz united states canada combination approved use united states sold brand name atripla bms structured collaboration joint venture operated limited liability company consolidated bms granted royaltyfree sublicenses joint venture use respective company owned technologies return granted certain licenses joint venture use intellectual property resulting collaboration economic interests joint venture held us bms including sharing revenues outofpocket expenses based portion net selling price atripla attributable truvada efavirenz since net selling price truvada changed time relative net selling price efavirenz bmss respective economic interests joint venture varied annually course collaboration agreement either party could terminate partys participation collaboration within days launch least one generic version partys single agent products double agent products terminating party right continue sell atripla become continuing party obligated pay terminated party certain royalties threeyear period following effective date termination december generic version efavirenz launched united states upon generic version launch terminated bmss participation collaboration became continuing party sole owner joint venture december last day collaboration result termination transfer gilead bmss ownership interest joint venture consolidate limited liability company whollyowned subsidiary bms longer ownership interest joint venture permitted commercialize atripla united states canada entitled receive us certain royalties net sales atripla next three calendar years declining annual scale may continue purchase efavirenz bms needed continue manufacturing atripla united states canada markets see note collaborative arrangements notes consolidated financial statements included item annual report additional information critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements included item annual report prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition product sales recognize revenues product sales persuasive evidence arrangement exists delivery occurred price fixed determinable collectability reasonably assured record product sales net estimated mandatory supplemental discounts government payers addition discounts private payers related charges generally referred grosstonet deductions recorded period related sales occur government rebates chargebacks represent majority grosstonet deductions require complex significant judgment management estimates assessed period updated reflect current information government rebates chargebacks government rebates chargebacks include amounts paid payers healthcare providers united states including medicaid rebates aids drug assistance programs veterans administration public health service discounts rebates well foreign government rebates rebates chargebacks based contractual arrangements statutory requirements may vary product payer individual payer plans qualified programs purchase products wholesalers distributors lower contractual price wholesalers distributors charge back us difference acquisition cost lower contractual price consolidated allowances government chargebacks payable direct customers classified reductions accounts receivable totaled million december million december consolidated allowance government rebates paid parties direct customers recorded accrued government rebates consolidated balance sheets totaled billion december billion december allowances government rebates chargebacks estimated based products sold historical utilization rates pertinent thirdparty industry information estimated patient population known market events trends channel inventory data andor market data also consider new information regarding changes programs regulations guidelines would impact amount actual rebates andor expectations regarding future utilization rates programs believe methodology use estimate government rebates chargebacks reasonable appropriate given current facts circumstances however actual results may differ significantly estimates last three years actual government rebates chargebacks claimed prior periods varied less estimates following table summarizes consolidated activities ending balances government rebates chargebacks accounts millions balance decreaseincrease balance end accrued government rebates chargebacks beginning year product sales payments year year ended december activity related sales activity related sales prior total year ended december activity related sales activity related sales prior total decrease government rebates chargebacks compared primarily driven lower hcv sales legal contingencies party various legal actions significant described note commitments contingencies legal proceedings notes consolidated financial statements included item annual report possible determine outcome matters recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine loss reasonably possible loss range loss estimated disclose possible loss significant judgment required determination probability determination whether exposure reasonably estimable inherent uncertainty unpredictability related matters accruals based believe best information available time assessment including legal facts circumstances case status proceedings applicable law views legal counsel upon final resolution matters possible may loss excess amount recorded amounts could material adverse effect results operations cash flows financial position periodically reassess matters additional information becomes available adjust estimates assumptions facts circumstances indicate need changes recognize accruals matters december believe losses probable valuation intangible assets conjunction business combinations recorded intangible assets primarily related iprd projects total intangible assets billion december compared billion december identifiable intangible assets measured respective fair values acquisition date may subject revision within measurement period may one year acquisition date models used valuing intangible assets require use significant estimates assumptions including limited estimates revenues operating profits related products product candidates probability success unapproved product candidates considering stages development time resources needed complete development approval product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets believe fair values used record intangible assets acquired connection business combination using information known knowable based upon reasonable estimates assumptions given facts circumstances related valuation dates intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts development complete generally occurs regulatory approval market product obtained associated assets would deemed finitelived would amortized based respective estimated useful lives point time period assets considered indefinite lived amortized tested impairment annual basis well annual tests become aware events changes would indicate likely fair values iprd projects respective carrying amounts fair value indefinite lived intangible assets dependent assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates significant judgment employed determining assumptions changes assumptions could significant impact results operations given period intangible assets finite useful lives amortized estimated useful lives primarily straightline basis intangible assets finite useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable october connection kite acquisition acquired intangible assets primarily related iprd axicabtagene ciloleucel kite ktec estimated aggregate fair value billion october fda approved axicabtagene ciloleucel known commercially yescarta making first car cell therapy treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy includes diffuse large bcell lymphoma transformed follicular lymphoma primary mediastinal bcell lymphoma upon approval reclassified billion purchased iprd finitelived intangible asset amortizing asset estimated useful life years using straightline method see note acquisitions notes consolidated financial statements included item annual report december indefinitelived intangible assets billion consisted purchased iprd acquisition kite see note acquisitions notes consolidated financial statements included item annual report estimated fair value iprd related momelotinib simtuzumab written zero due termination clinical developments programs result recorded impairment charges million within research development expenses consolidated statements income included item annual report provision income taxes estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made valuation allowance million december million december increase valuation allowance december december primarily related kite subject income taxes united states various foreign jurisdictions including ireland due economic political conditions various countries actively considering made changes existing tax laws example united states recently enacted significant tax reform certain provisions new law significantly affect us predict form timing potential legislative changes could material adverse impact results operations addition significant judgment required determining worldwide provision income taxes december tax reform signed law united states making significant changes internal revenue code amended changes include limited corporate tax rate decrease effective tax years beginning december implementation modified territorial tax system repatriation tax deemed repatriated earnings foreign subsidiaries calculated provisional estimate impact tax reform income tax provision accordance interpretation tax reform guidance available date filing result recorded estimated billion net charge income tax expense fourth quarter period tax reform enacted amount includes provisional million deferred tax benefit related remeasurement certain deferred tax assets liabilities based revised rates expected reverse future ii provisional billion charge related transition tax mandatory deemed repatriation accumulated foreign earnings determined december provisional transition tax charge includes federal net certain offsetting adjustments related unrecognized tax benefits state local foreign withholding tax accumulated foreign earnings longer considered indefinitely reinvested december accordance sec sab determined million deferred tax benefit recorded connection remeasurement certain deferred tax assets liabilities billion current tax expense recorded connection transition tax mandatory deemed repatriation foreign earnings provisional subject adjustment measurement period exceed one year enactment tax reform given complexity tax reform may refining estimates provisional amounts guidance issued us treasury sec fasb additionally continuing evaluate accounting policy election required regard tax global intangible lowtaxed income global minimum tax fasb allows companies adopt policy election account global minimum tax one two methods account global minimum tax component tax expense period company subject rules period cost method ii account global minimum tax companys measurement deferred taxes deferred method elected method completion analysis global minimum tax provisions election method depend part analyzing expected future us taxable income inclusions related global minimum tax methodologies order determine appropriate method decide elect deferred method accounting global minimum tax possible provisional estimate remeasuring deferred taxes may materially change finalize analysis accounting policy election measurement period record liabilities related unrecognized tax benefits accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return adverse resolution one uncertain tax positions period could material impact results operations period total unrecognized tax benefits billion december recognized would reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefits decrease approximately million next months due potential settlement tax examinations lapse statute limitations file federal state foreign income tax returns united states many foreign jurisdictions federal california income tax purposes statute limitations open onwards certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years income tax returns subject audit federal state foreign tax authorities currently examination irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions see note income taxes notes consolidated financial statements included item annual report additional information balance sheet arrangements balance sheet arrangements defined item aii regulation sk contractual obligations contractual obligations consist debt obligations operating leases capital commitments purchase obligations active pharmaceutical ingredients inventoryrelated items clinical trials contracts following table summarizes significant enforceable legally binding obligations future commitments obligations related contracts likely continue regardless fact certain obligations may cancelable december millions payments due period less one contractual obligations total year years years years debt operating lease obligations capital commitments purchase obligations clinical trials transition tax payable total notes debt primarily consisted senior unsecured notes term loan facilities including principal interest payments interest payments fixed rate senior unsecured notes incurred calculated based terms related notes interest payments variable rate debt calculated based interest rates last reset date debt instrument see note debt credit facilities notes consolidated financial statements included item annual report additional information amounts include firm capital project commitments primarily relating construction new buildings amounts include firm purchase commitments primarily relating active pharmaceutical ingredients certain inventoryrelated items amounts include minimum purchase requirements addition committed make potential future milestone payments third parties part licensing collaboration development arrangements payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded consolidated balance sheets included table december several clinical studies various clinical trial phases significant clinical trial expenditures contract research organizations cros although material contracts cros cancelable historically canceled contracts amounts reflect commitments based existing contracts reflect future modifications terminations existing contracts anticipated potential new contracts connection tax reform december recorded federal income tax payable billion transition tax mandatory deemed repatriation foreign earnings amounts included table represent federal income tax payable billion transition tax payable eight year period amounts associated tax reform considered provisional may subject adjustment measurement period see note income taxes notes consolidated financial statements included item annual report additional details tax reform december longterm income taxes payable include unrecognized tax benefits interest penalties totaling billion due high degree uncertainty timing future cash settlement events could extinguish unrecognized tax benefits unable estimate period cash settlement therefore excluded unrecognized tax benefits table recent accounting pronouncements information required item included note organization summary significant accounting policies notes consolidated financial statements included item annual report item quantitative qualitative disclosures market risk exposed market risks may result changes foreign currency exchange rates interest rates credit risks market price reduce certain risks enter various types foreign currency interest rate derivative hedging transactions follow investment guidelines monitor outstanding receivables part risk management program foreign currency exchange risk operations include manufacturing sales activities united states canada ireland well sales activities countries outside united states including europe asia pacific result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business approximately product sales denominated foreign currencies partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales may enter foreign currency exchange forward option contracts also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged december open foreign currency forward contracts notional amounts billion billion respectively hypothetical adverse movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million date realized would negatively affect earnings remaining life contracts hypothetical movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million date realized would negatively affect earnings remaining life contracts analysis consider impact hypothetical changes foreign currency exchange rates would anticipated transactions foreign currency sensitive instruments designed offset interest rate risk portfolio availableforsale marketable securities fixed variable rate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestgenerating assets interestbearing liabilities december millions except percentages expected maturity total fair thereafter total value assets availableforsale debt securities average interest rate liabilities longterm debt including current portion fixed rate average interest rate variable rate average interest rate notes amounts represent principal balances addition fixed variable rate longterm debt billion fiveyear revolving credit facility amounts outstanding fiveyear revolving credit facility december see note debt credit facilities notes consolidated financial statements included item annual report additional information billion principal amount fiveyear senior unsecured term loan facility issued october payable quarterly amounts equal initial principal amount fiscal quarter end date starting fourth quarter remaining balance due payable maturity average interest rates variable rate debt based interest rates last reset date debt instrument dependent upon several factors subject change including limited libor principal amount debt outstanding credit ratings reset date credit risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe december accounts receivable net southern europe specifically greece italy portugal spain totaled approximately million million greater days past due including million greater days past due december accounts receivable net southern europe specifically greece italy portugal spain totaled approximately million million greater days past due including million greater days past due date experienced significant losses respect collection accounts receivable market price risk hold million shares common stock galapagos clinicalstage biotechnology company based belgium connection license collaboration agreement entered galapagos equity security classified availableforsale security fair value approximately million million december respectively yearoveryear increase due increase common stock price galapagos availableforsale equity security subject potential changes fair value due volatility stock market changes general economic conditions among factors hypothetical decrease stock price investment would decrease fair value december approximately million monitor investment temporary decline fair value would record impairment loss income temporary decline fair value occurs item financial statements supplementary data gilead sciences inc index consolidated financial statements supplementary data years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements comprehensive income consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements selected quarterly financial information unaudited schedule ii valuation qualifying accounts report independent registered public accounting firm stockholders board directors gilead sciences inc opinion financial statements audited accompanying consolidated balance sheets gilead sciences inc company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes financial statement schedule listed index item collectively referred consolidated financial statements opinion consolidated financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity us generally accepted accounting principles also audited accordance standards public company accounting oversight board united states pcaob companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon basis opinion financial statements responsibility companys management responsibility express opinion companys financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion ernst young llp served companys auditor since redwood city california february gilead sciences inc consolidated balance sheets millions except per share amounts december assets current assets cash cash equivalents shortterm marketable securities accounts receivable net allowances december december inventories prepaid current assets total current assets property plant equipment net longterm marketable securities intangible assets net goodwill longterm assets total assets liabilities stockholders equity current liabilities accounts payable accrued government rebates accrued liabilities current portion longterm debt obligations net total current liabilities longterm debt net longterm income taxes payable longterm obligations commitments contingencies note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized december december shares issued outstanding december december additional paidin capital accumulated comprehensive income retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity see accompanying notes gilead sciences inc consolidated statements income millions except per share amounts year ended december revenues product sales royalty contract revenues total revenues costs expenses cost goods sold research development expenses selling general administrative expenses total costs expenses income operations interest expense income expense net income provision income taxes provision income taxes net income net income loss attributable noncontrolling interest net income attributable gilead net income per share attributable gilead common stockholders basic shares used per share calculation basic net income per share attributable gilead common stockholders diluted shares used per share calculation diluted cash dividends declared per share see accompanying notes gilead sciences inc consolidated statements comprehensive income millions year ended december net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale securities net unrealized gain loss net tax impact respectively reclassifications net income net tax impact respectively net change cash flow hedges net unrealized gain loss net tax impact respectively reclassification net income net tax impact respectively net change comprehensive income loss comprehensive income comprehensive income loss attributable noncontrolling interest comprehensive income attributable gilead see accompanying notes gilead sciences inc consolidated statements stockholders equity millions gilead stockholders equity common stock accumulated additional total paidin comprehensive retained noncontrolling stockholders shares amount capital income loss earnings interest equity balance december change noncontrolling interest net income loss comprehensive loss net tax issuances employee stock purchase plan issuances equity incentive plans tax benefits employee stock plans stockbased compensation repurchases common stock warrants settlement convertible notes settlement convertible note hedges settlement dividends declared reclassification equity component currently redeemable convertible notes balance december change noncontrolling interest net income loss comprehensive income net tax issuances employee stock purchase plan issuances equity incentive plans tax benefits employee stock plans stockbased compensation repurchases common stock warrants settlement convertible notes settlement convertible note hedges settlement dividends declared reclassification conversion spread convertible notes reclassification convertible note hedges reclassification equity component currently redeemable convertible notes balance december change noncontrolling interest net income comprehensive loss net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared balance december see accompanying notes gilead sciences inc consolidated statements cash flows millions year ended december operating activities net income adjustments reconcile net income net cash provided operating activities depreciation expense amortization expense stockbased compensation expense deferred income taxes inprocess research development impairment changes operating assets liabilities accounts receivable net inventories prepaid expenses accounts payable income taxes payable accrued liabilities net cash provided operating activities investing activities purchases marketable securities proceeds sales marketable securities proceeds maturities marketable securities investments acquisitions net cash acquired capital expenditures net cash used investing activities financing activities proceeds debt financing net issuance costs proceeds convertible note hedges proceeds issuances common stock repurchases common stock repayments debt obligations payments settle warrants payment dividends net cash provided used financing activities effect exchange rate changes cash cash equivalents net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid net amounts capitalized income taxes paid see accompanying notes gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world operations countries worldwide headquarters foster city california gileads primary areas focus include hivaids liver diseases hematologyoncology inflammationrespiratory diseases seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategies portfolio marketed products includes ambisome atripla biktarvy cayston compleraeviplera descovy emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada tybost vemlidy viread vosevi yescartatm zydelig us international commercial sales operations marketing subsidiaries countries also sell distribute certain products corporate partners royaltypaying collaborative agreements basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries certain variable interest entities primary beneficiary intercompany transactions eliminated consolidated entities exposed less economics record net income loss attributable noncontrolling interests consolidated statements income equal percentage economic ownership interest retained entities respective noncontrolling parties assess whether primary beneficiary variable interest entity vie inception arrangement reporting date assessment based power direct activities vie significantly impact vies economic performance obligation absorb losses right receive benefits vie could potentially significant vie december material vie joint venture bristolmyers squibb company bms described note collaborative arrangements december last day joint venture bms united states canada significant accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate significant accounting policies estimates base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates revenue recognition product sales recognize revenue product sales persuasive evidence arrangement exists delivery occurred price fixed determinable collectability reasonably assured upon recognition revenue product sales provisions made government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products appropriate items deducted gross product sales rebates chargebacks estimate reductions revenues amounts paid payers healthcare providers united states including medicaid rebates aids drug assistance programs veterans administration public health service discounts rebates well foreign government rebates rebates chargebacks based contractual arrangements statutory requirements may vary product payer individual payer plans estimates based products sold historical utilization rates available pertinent thirdparty industry information estimated patient population known market events trends us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements also take consideration available new information regarding changes programs regulations guidelines would impact amount actual rebates andor expectations regarding future utilization rates programs government chargebacks payable direct customers classified reductions accounts receivable consolidated balance sheets government rebates invoiced directly us recorded accrued government rebates consolidated balance sheets cash discounts estimate cash discounts based contractual terms historical utilization rates expectations regarding future utilization rates distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractually determined covenants maintenance agreed upon inventory levels distributor fees based contractually determined fixed percentage sales product returns provide customers general right product return typically permit returns product damaged defective received customer case product sold united states certain countries outside united states product expired accept returns product expire within six months expired one year expiration dates estimates expected returns expired products based primarily ongoing analysis historical return patterns historical industry information reporting return rates similar products contractual agreements intended limit amount inventory maintained wholesalers royalty revenues royalty revenue sales products generally recognized received generally quarter following quarter corresponding sales occur month following month corresponding sales occur research development expenses research development rd expenses consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations cros materials supplies licenses fees upfront milestone payments collaboration arrangements overhead allocations consisting various support facilityrelated costs charge rd costs including clinical study costs expense incurred clinical study costs significant component rd expenses clinical studies performed thirdparty cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros material cro contracts terminable us upon written notice generally liable actual services completed cro certain noncancelable expenses incurred point termination selling general administrative expenses selling general administrative sga expenses relate sales marketing finance human resources legal administrative activities sga expenses consist primarily personnel costs facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses also include branded prescription drug bpd fee expense costs advertising including promotional expenses incurred advertising expenses million million million cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents eligible instruments investment policy included cash equivalents primarily include commercial paper money market funds overnight repurchase agreements major banks authorized dealers bank obligations marketable nonmarketable securities marketable debt securities determine appropriate classification marketable securities time purchase reevaluate designation balance sheet date marketable securities considered availableforsale carried estimated fair values reported cash equivalents shortterm marketable securities longterm marketable securities unrealized gains losses availableforsale securities excluded net income reported accumulated comprehensive income loss aoci separate component stockholders equity income expense net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities otherthantemporary declines fair value securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position severity duration unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carrying value security hold record loss amount decline marketable nonmarketable equity securities record investments public companies availableforsale securities fair market value also invest equity securities companies whose securities publicly traded fair value readily available investments recorded using either cost method equity method accounting depending ownership percentage factors indicate significant influence investments recorded assets unrealized gains losses availableforsale securities excluded net income reported aoci regularly review securities indicators impairment investments nonpublic companies material periods presented concentrations risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe japan date experienced significant losses respect collection accounts receivable believe allowance doubtful accounts adequate december certain raw materials components utilize operations obtained single suppliers certain raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship commercial products supply product candidates clinical trials accounts receivable trade accounts receivable recorded net allowances wholesaler chargebacks related government programs cash discounts prompt payment doubtful accounts estimates wholesaler chargebacks government programs cash discounts based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices historically amounts uncollectible accounts receivable written insignificant inventories inventories recorded lower cost net realizable value cost determined firstin firstout basis periodically review composition inventories order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized future commercialization considered probable future economic benefit expected realized based managements judgment capitalize prelaunch inventory costs prior regulatory approval number factors taken consideration including current status regulatory approval process potential impediments approval process safety efficacy anticipated rd initiatives could impact indication compound used viability commercialization marketplace trends december amount prelaunch inventory consolidated balance sheets significant property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straight line method repairs maintenance costs expensed incurred estimated useful lives years generally follows description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term office computer equipment includes capitalized software unamortized capitalized software costs consolidated balance sheets million december million december capitalized interest construction inprogress included property plant equipment interest capitalized significant acquisitions account business combinations using acquisition method accounting requires assets acquired including inprocess research development iprd projects liabilities assumed recorded fair values acquisition date consolidated balance sheets excess purchase price fair value net assets acquired recorded goodwill determination estimated fair value requires us make significant estimates assumptions result may record adjustments fair values assets acquired liabilities assumed within measurement period one year acquisition date corresponding offset goodwill transaction costs associated business combinations expensed incurred determine net assets acquired meet definition business combination acquisition method accounting acquired iprd expensed goodwill recorded goodwill intangible assets goodwill represents excess consideration transferred estimated fair value assets acquired liabilities assumed business combination intangible assets indefinite useful lives related purchased iprd projects measured respective fair values acquisition date amortize goodwill intangible assets indefinite useful lives intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts development complete generally occurs regulatory approval market product obtained associated assets deemed finitelived amortized based respective estimated useful lives point time test goodwill indefinitelived intangible assets impairment annual basis annual tests become aware events changes would indicate fair values assets carrying amounts intangible assets finite useful lives amortized estimated useful lives primarily straightline basis reviewed impairment facts circumstances suggest carrying value assets may recoverable impairment longlived assets longlived assets including property plant equipment finitelived intangible assets reviewed impairment whenever facts circumstances either internally externally may suggest carrying value asset asset group may recoverable indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset asset group eventual disposition carrying amount asset asset group excess carrying value asset asset group estimated fair value recognized impairment loss foreign currency translation transaction gains losses hedging contracts nonus entity operations recorded functional currency entity results operations nonus dollar functional currency entities translated us dollars using average currency rates assets liabilities translated using currency rates period end foreign currency translation adjustments recorded component aoci within stockholders equity foreign currency transaction gains losses recorded income expense net consolidated statements income net foreign currency transaction gains losses immaterial years ended december hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes fair value financial instruments apply fair value accounting financial assets liabilities nonfinancial assets liabilities recognized disclosed fair value financial statements recurring basis define fair value price would received selling asset paid transfer liability orderly transaction market participants measurement date determining fair value measurements assets liabilities required recorded fair value consider principal advantageous market would transact marketbased risk measurements assumptions market participants would use pricing asset liability risks inherent valuation techniques transfer restrictions credit risks derivative financial instruments recognize derivative instruments either assets liabilities fair value consolidated balance sheets changes fair value derivatives recorded period current earnings aoci depending whether derivative designated part hedge transaction type hedge transaction classify cash flows instruments category cash flows hedged items hold issue derivative instruments trading speculative purposes assess inception ongoing basis whether derivatives used hedging transactions highly effective offsetting changes cash flows fair values hedged items also assess hedge ineffectiveness quarterly basis record gain loss related ineffective portion current earnings extent significant determine forecasted transaction probable occurring discontinue hedge accounting affected portion hedge instrument related unrealized gain loss contract recognized income expense net consolidated statements income income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations applicable tax laws regulations record liabilities related unrecognized tax benefits accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return adverse resolution one uncertain tax positions period could material impact results operations period recently adopted accounting pronouncements november financial accounting standards board fasb issued accounting standards update asu balance sheet classification deferred taxes adopted standard retrospective basis first quarter asu requires deferred tax assets liabilities classified noncurrent balance sheet result consolidated balance sheets december retrospectively adjusted resulting reduction total current assets million increase longterm assets million resulting reclassification deferred tax liabilities material march fasb issued accounting standards update asu improvements employee sharebased payment accounting adopted standard january one aspect standard requires excess tax benefits deficiencies arise upon vesting exercise share based awards recognized income statement prospective basis previous guidance tax effects recorded additional paidin capital result recognized million excess tax benefits provision income taxes consolidated statements income resulting impact shares used calculation diluted earnings per share material additionally allowed standard elected continue estimate potential forfeitures another aspect asu amended presentation certain sharebased payment items statement cash flows adopted retrospective basis result consolidated statements cash flows adjusted reclassify million million respectively excess tax benefits stockbased compensation net cash used financing activities net cash provided operating activities b reclassify million million respectively employee taxes paid tax authorities withheld shares meet minimum statutory withholding requirement changes accrued liabilities within net cash provided operating activities within net cash used financing activities january fasb issued accounting standards update asu clarifying definition business asu clarifies definition business evaluating whether transactions accounted acquisitions disposals assets businesses anticipate transactions accounted asset acquisitions rather business acquisitions provisions new standard adopted standard prospective basis fourth quarter impact adoption material effect consolidated financial statements recently issued accounting pronouncements yet adopted may fasb issued accounting standards update asu revenue contracts customers standards core principle reporting entity recognize revenue transfers promised goods services customers amount reflects consideration entity expects entitled exchange goods services standard become effective us beginning first quarter early adoption permitted entities option using either full retrospective modified retrospective approach adopt new guidance fasb issued supplemental adoption guidance clarification asu march april may december within asu revenue contracts customers principal versus agent considerations asu revenue contracts customers identifying performance obligations licensing asu revenue contracts customers narrowscope improvements practical expedients asu technical corrections improvements topic revenue contracts customers respectively adopting standards using modified retrospective approach cumulative effect adopting standards recorded retained earnings january completed assessment effect adoption based assessment accelerate recognition royalty revenues certain revenues recognized cash basis sell method periods sales occur subject constraint variable consideration expect adoption standards material impact consolidated financial statements january fasb issued accounting standards update asu financial instruments overall recognition measurement financial assets financial liabilities asu changes accounting equity investments financial liabilities fair value option presentation disclosure requirements financial instruments addition clarified guidance related valuation allowance assessment recognizing deferred tax assets resulting unrealized losses availableforsale debt securities guidance become effective us beginning first quarter must adopted using modified retrospective approach certain exceptions early adoption permitted certain provisions plan adopt guidance first quarter expect impact primarily related recognition measurement equity investment galapagos nv galapagos reclassify unrealized net gain aoci retained earnings date adoption primarily comprises million unrealized gain based fair value equity investment galapagos december february fasb issued accounting standards update asu leases asu amends number aspects lease accounting including requiring lessees recognize almost leases term greater one year rightofuse asset corresponding liability measured present value lease payments guidance become effective us beginning first quarter required adopted using modified retrospective approach early adoption permitted evaluating impact adoption standard anticipate recognition additional assets corresponding liabilities related leases consolidated balance sheets june fasb issued accounting standards update asu financial instruments credit losses measurement credit losses financial instruments asu requires measurement recognition expected credit losses financial assets guidance become effective us beginning first quarter must adopted using modified retrospective approach certain exceptions early adoption permitted beginning first quarter evaluating impact adoption standard consolidated financial statements fair value measurements determine fair value financial nonfinancial assets liabilities using fair value hierarchy establishes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability marketable securities review trading activity pricing measurement date sufficient quoted pricing identical securities available use market pricing observable market inputs similar securities obtained various thirdparty data providers inputs either represent quoted prices similar assets active markets derived observable market data level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques significant management judgment estimation financial instruments consist primarily cash cash equivalents marketable securities accounts receivable foreign currency exchange contracts equity securities accounts payable shortterm longterm debt cash cash equivalents marketable securities foreign currency exchange contracts equity securities reported respective fair values consolidated balance sheets shortterm longterm debt reported amortized costs consolidated balance sheets remaining financial instruments reported consolidated balance sheets amounts approximate current fair values transfers level level level periods presented following table summarizes types assets liabilities measured fair value recurring basis level within fair value hierarchy millions december december level level level total level level level total assets corporate debt securities certificates deposit money market funds us treasury securities residential mortgage assetbacked securities us government agencies securities nonus government securities municipal debt securities equity securities deferred compensation plan foreign currency derivative contracts total liabilities deferred compensation plan foreign currency derivative contracts contingent consideration total level inputs estimate fair values level instruments taking consideration valuations obtained thirdparty pricing services pricing services utilize industry standard valuation models including income marketbased approaches significant inputs observable either directly indirectly estimate fair value inputs include reported trades brokerdealer quotes similar securities issuer credit spreads benchmark securities prepaymentdefault projections based historical data observable inputs substantially foreign currency derivative contracts maturities within month time horizon counterparties minimum credit rating equivalent sp global ratings moodys investors service inc fitch ratings inc estimate fair values contracts taking consideration valuations obtained thirdparty valuation service utilizes incomebased industry standard valuation model significant inputs observable either directly indirectly inputs include foreign currency exchange rates london interbank offered rates libor swap rates inputs applicable observable commonly quoted intervals total estimated fair values shortterm longterm debt determined using level inputs based quoted market values approximately billion billion december respectively carrying values billion billion december respectively level inputs december assets liabilities measured using level inputs recurring basis contingent consideration liabilities immaterial nonrecurring basis measure certain assets including intangible assets fair value carrying value asset exceeds fair value estimated fair value iprd related momelotinib simtuzumab written zero due termination clinical developments programs result recorded impairment charges million policy recognize transfers level classification actual date event change circumstances caused transfer availableforsale securities estimated fair values availableforsale securities generally based prices obtained commercial pricing services following summarizes availableforsale securities millions december december gross gross gross gross amortized unrealized unrealized estimated amortized unrealized unrealized estimated cost gains losses fair value cost gains losses fair value corporate debt securities certificates deposit money market funds us treasury securities residential mortgage assetbacked securities us government agencies securities nonus government securities municipal debt securities equity securities total following table summarizes classification availableforsale securities consolidated balance sheets millions december december cash cash equivalents shortterm marketable securities prepaid current assets longterm marketable securities longterm assets total cash cash equivalents table excludes cash billion billion december respectively following table summarizes availableforsale securities contractual maturity millions december amortized cost fair value within one year one year five years five years ten years ten years total following table summarizes availableforsale securities continuous unrealized loss position deemed otherthan temporarily impaired millions less months months greater total gross gross gross unrealized estimated unrealized estimated unrealized estimated losses fair value losses fair value losses fair value december corporate debt securities us treasury securities residential mortgage assetbacked securities us government agencies securities nonus government securities total december corporate debt securities us treasury securities residential mortgage assetbacked securities us government agencies securities nonus government securities certificates deposit municipal debt securities total held total positions december respectively related debt securities unrealized loss position based review availableforsale securities believe otherthantemporary impairments securities december intend sell securities believe required sell securities recovery amortized cost basis gross realized gains gross realized losses immaterial years ended december derivative financial instruments operations foreign countries expose us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies primarily euro order manage risk may hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge exposure foreign currency exchange rate fluctuations certain monetary assets liabilities entities denominated non functional currency derivative instruments use hedge exposure designated hedges result changes fair value recorded income expense net consolidated statements income hedge exposure foreign currency exchange rate fluctuations forecasted product sales denominated nonfunctional currency derivative instruments use hedge exposure designated cash flow hedges maturities months less upon executing hedging contract quarterly thereafter assess prospective hedge effectiveness using regression analysis calculates change cash flow result hedge instrument quarterly basis assess retrospective hedge effectiveness using dollar offset approach exclude time value effectiveness testing recognize changes time value hedge income expense net consolidated statements income effective component hedge recorded unrealized gain loss hedging instrument aoci within stockholders equity consolidated balance sheets gains losses reclassified product sales hedged transactions affect earnings majority gains losses related hedged forecasted transactions reported aoci december expected reclassified product sales within months cash flow effects derivative contracts three years ended december included within net cash provided operating activities consolidated statements cash flows notional amounts foreign currency exchange contracts outstanding billion billion december respectively derivative contracts allow us right offset assets liabilities presented amounts gross basis international swap dealers association inc master agreements respective counterparties foreign currency exchange contracts subject applicable requirements allowed net settle transactions currency single net amount payable one party following table summarizes classification fair values derivative instruments consolidated balance sheets millions december asset derivatives liability derivatives fair classification fair value classification value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities total derivatives designated hedges total derivatives december asset derivatives liability derivatives fair classification fair value classification value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges total derivatives following table summarizes effect foreign currency exchange contracts consolidated financial statements millions year ended december derivatives designated hedges gains losses recognized aoci effective portion gains losses reclassified aoci product sales effective portion gains losses recognized income expense net ineffective portion amounts excluded effectiveness testing derivatives designated hedges gains losses recognized income expense net time time may discontinue cash flow hedges result record related amounts income expense net consolidated statements income material amounts recorded income expense net years ended december result discontinuance cash flow hedges december held one type financial instrument derivative contracts related foreign currency exchange contracts following table summarizes potential effect offsetting derivatives type financial instrument consolidated balance sheets millions december offsetting derivative assetsliabilities gross amounts offset consolidated balance sheets gross amounts offset amounts assetsliabilities gross amounts consolidated balance presented consolidated derivative financial cash collateral net amount description recognized assetsliabilities sheets balance sheets instruments receivedpledged legal offset derivative assets derivative liabilities december offsetting derivative assetsliabilities gross amounts offset consolidated balance sheets gross amounts offset amounts assetsliabilities gross amounts consolidated balance presented consolidated derivative financial cash collateral net amount description recognized assetsliabilities sheets balance sheets instruments receivedpledged legal offset derivative assets derivative liabilities may convertible senior notes convertible note hedges march exercised option elect cash settlement conversion value excess principal amount conversion spread remaining convertible senior notes due may convertible notes related convertible note hedges cash settlement election conversion spread convertible notes convertible note hedges met applicable criteria equity classification therefore recorded stockholders equity consolidated balance sheets upon cash settlement election reclassified million fair value conversion spread stockholders equity current portion longterm debt obligations net reclassified million fair value convertible note hedges stockholders equity prepaid current assets consolidated balance sheets upon maturity convertible notes settled conversion spread convertible note hedges cash million respectively recorded loss million conversion spread gain million convertible note hedges consolidated statements income acquisitions kite pharma inc october acquisition date completed tender offer outstanding common stock kite pharma inc kite per share cash result kite became whollyowned subsidiary acquisition kite helps establish foundation improving treatment hematological malignancies solid tumors kites cell therapies express either chimeric antigen receptor car engineered cell receptor depending type cancer kites advanced therapy candidate axicabtagene ciloleucel car cell therapy october axicabtagene ciloleucel known commercially yescarta approved fda making first car cell therapy treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy includes diffuse large bcell lymphoma dlbcl transformed follicular lymphoma tfl primary mediastinal bcell lymphoma pmbcl marketing authorization application also filed axicabtagene ciloleucel treatment relapsedrefractory dlbcl tfl pmbcl european medicines agency kite additional candidates clinical trials hematologic cancers solid tumors including kite car cell therapy candidate targets bcell maturation antigen expressed multiple myeloma consideration transferred acquisition million consisting million cash outstanding kite common stockholders million cash payment vested equity award holders million warrant holders approximately million representing portion replaced stock based awards attributable precombination period addition approximately million excluded consideration transferred representing portion replaced stockbased awards attributable post combination period million recognized compensation expense three months ended december remaining stockbased compensation expense replacement awards expected recognized financed transaction billion aggregate principal amount senior unsecured notes issued september billion aggregate principal amount term loan facility credit agreement entered september drawn october well cash hand see note debt credit facilities additional information acquisition kite accounted business combination using acquisition method accounting method requires among things assets acquired liabilities assumed recognized fair value acquisition date fair value estimates assets acquired liabilities assumed based upon preliminary valuations using information known knowable date filing able complete valuation obtain additional information primarily related certain forecast assumptions used perform preliminary valuation intangibles estimates record benefit certain tax attributes changes assumptions estimates could cause impact valuation assets acquired including intangible assets goodwill related tax impacts acquisition following table summarizes preliminary acquisition date fair values assets acquired liabilities assumed consideration transferred millions cash cash equivalents identifiable intangible assets indefinitelived intangible assets iprd outlicense acquired deferred income taxes assets acquired liabilities assumed net total identifiable net assets goodwill total consideration transferred identifiable intangible assets acquired intangible assets primarily related iprd axicabtagene ciloleucel kite ktec estimated aggregate fair value million acquisition date fair values assets determined using probabilityweighted income approach discounts expected future cash flows present value estimated net cash flows discounted using discount rate based estimated weightedaverage cost capital companies profiles similar kite rate comparable estimated internal rate return acquisition represents rate market participants would use value intangible assets projected cash flows iprd assets based key assumptions estimates revenues operating profits related project considering stage development acquisition date time resources needed complete development approval product candidates life potential commercialized product associated risks including inherent difficulties uncertainties developing product candidate obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived assets completion abandonment associated rd efforts october upon fda approval yescarta treatment adult patients relapsed refractory dlbcl two lines systemic therapy million purchased iprd reclassified finitelived intangible asset amortized estimated useful life years using straight line method additionally acquired outlicense daiichi sankyo estimated fair value million acquisition date definitelived intangible asset amortized estimated useful life years straightline basis fair value determined estimating probability weighted net cash flows attributable outlicense discounted present value using discount rate represents estimated rate market participants would use value intangible asset goodwill million goodwill represents excess consideration transferred fair values assets acquired liabilities assumed represents future economic benefits arising assets acquired could individually identified separately recognized none goodwill deductible income tax purposes actual supplemental pro forma information financial results kite since date acquisition included consolidated statements income year ended december kites pretax operating loss approximately million included expenses million associated acquisition kite kites pretax operating loss included million sharebased compensation expenses million due accelerated vesting compensation charges associated acquisition million acquired iprd expenses primarily related acquisition cell design labs inc cell design labs million amortization intangible assets sharebased compensation expenses recorded primarily within research development expenses selling general administrative expenses acquired iprd expenses recorded within research development expenses amortization expense recorded within cost goods sold consolidated statements income year ended december connection acquisition kite incurred million transaction costs recorded within selling general administrative expenses consolidated statements income year ended december following pro forma information presents combined results operations gilead kite acquisition kite completed january adjustments give effect pro forma events directly attributable acquisition millions unaudited year ended december total revenues net income attributable gilead unaudited pro forma consolidated results include pro forma adjustments directly attributable acquisition assuming acquisition occurred january primary adjustments include compensation expenses million acquisitionrelated transaction expenses million inclusive kites transaction expenses incurred included net income attributable gilead year ended december ii impact additional interest expense debt issued connection acquisition kite assuming debt incurred january unaudited pro forma results reflect operating efficiencies potential cost savings may result consolidation operations gilead kite accordingly unaudited pro forma results presented informational purposes necessarily indicative actual results operations combined company would acquisition occurred beginning indicative future results operations cell design labs inc december acquired issued outstanding stock cell design labs privately held company addition approximately shares cell design labs obtained acquisition kite acquisition gained new technology platforms enhance research development efforts cellular therapy cash consideration totaled million net acquired cash additionally shareholders cell design labs us eligible receive contingent development regulatory milestonebased payments million equity interest cell design labs carrying value million transaction accounted asset acquisition result million expensed acquired iprd within research development expenses consolidated statements income nimbus apollo inc may acquired nimbus apollo inc privately held company acetylcoa carboxylase inhibitor program evaluated potential treatment nonalcoholic steatohepatitis hepatocellular carcinoma diseases consideration included payment million contingent development regulatory milestonebased payments million transaction accounted asset acquisition result payment million expensed acquired iprd within research development expenses consolidated statements income based achievement certain clinical development milestones recorded million expense within research development expenses consolidated statements income inventories inventories summarized follows millions december raw materials work process finished goods total reported inventories longterm assets total amounts reported longterm assets primarily consisted raw materials december joint ventures bms consolidate held efavirenz active pharmaceutical ingredient inventory efavirenz inventory purchased bms bmss estimated net selling price efavirenz december generic version efavirenz launched united states upon generic version launch terminated bmss participation collaboration united states canada became sole owner joint venture countries december last day collaboration united states canada result termination pursuant terms existing agreements governing collaboration united states canada recorded million reduction inventory receivable bms adjust purchase price inventory hand termination date remaining collaborative arrangements bms continue purchase efavirenz bms bmss estimated net selling price efavirenz see note collaborative arrangements additional information december efavirenz inventory valued bmss estimated net selling price totaled million billion respectively property plant equipment property plant equipment summarized follows millions december land buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment construction progress subtotal less accumulated depreciation amortization total intangible assets goodwill following table summarizes carrying amount intangible assets net millions december finitelived intangible assets indefinitelived intangible assets total finitelived intangible assets following table summarizes finitelived intangible assets millions december december gross carrying accumulated net carrying gross carrying accumulated net carrying amount amortization amount amount amortization amount intangible asset sofosbuvir intangible asset axicabtagene ciloleucel dlbcl intangible asset ranexa total amortization expense related finitelived intangible assets included primarily cost goods sold consolidated statements income totaled million million million december estimated future amortization expense associated finitelived intangible assets follows millions fiscal year amount thereafter total indefinitelived intangible assets december indefinitelived intangible assets million consisted purchased iprd acquisition kite see note acquisitions additional information estimated fair value iprd related momelotinib simtuzumab written zero due termination clinical development programs result recorded impairment charges million within research development expenses consolidated statements income goodwill upon completing acquisition kite october preliminarily attributed million goodwill consolidated balance sheets following table summarizes changes carrying amount goodwill millions balance december goodwill resulting acquisition kite balance december financial information accrued liabilities components accrued liabilities summarized follows millions december income taxes payable compensation employee benefits bpd fee accrued expenses total collaborative arrangements enter collaborative arrangements third parties development commercialization certain products parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities following significant collaborative arrangements bristolmyers squibb company north america entered collaboration arrangement bms develop commercialize single tablet regimen containing truvada bmss sustiva efavirenz united states canada combination approved use united states sold brand name atripla bms structured collaboration joint venture operated limited liability company consolidated bms granted royaltyfree sublicenses joint venture use respective company owned technologies return granted certain licenses joint venture use intellectual property resulting collaboration economic interests joint venture held us bms including sharing revenues outofpocket expenses based portion net selling price atripla attributable truvada efavirenz since net selling price truvada changed time relative net selling price efavirenz bmss respective economic interests joint venture varied annually course collaboration agreement either party could terminate partys participation collaboration within days launch least one generic version partys single agent products double agent products terminating party right continue sell atripla become continuing party obligated pay terminated party certain royalties threeyear period following effective date termination december generic version efavirenz launched united states upon generic version launch terminated bmss participation collaboration became continuing party sole owner joint venture december last day collaboration result termination transfer gilead bmss ownership interest joint venture consolidate limited liability company whollyowned subsidiary bms longer ownership interest joint venture permitted commercialize atripla united states canada entitled receive us certain royalties net sales atripla next three calendar years declining annual scale may continue purchase efavirenz bms needed continue manufacturing atripla united states canada markets transfer bmss ownership interest joint venture us accounted equity transaction reduced associated noncontrolling interest zero reflect derecognition bmss ownership interest difference consideration payable bms amount noncontrolling interest insignificant recorded reduction additional paidincapital apic associated cash flow effect transfer bmss ownership interest reflected cash used financing activities consolidated statements cash flows year ended december amount settled december joint venture held efavirenz active pharmaceutical ingredient purchased bms bmss estimated net selling price efavirenz us market amounts primarily included inventories consolidated balance sheets december selected financial information joint venture follows millions december total assets cash cash equivalents accounts receivable net inventories total liabilities accounts payable accrued liabilities asset liability amounts reflect impact intercompany eliminations included consolidated balance sheets although consolidated joint venture legal structure joint venture limited recourse creditors could general credit assets similarly assets held joint venture could used settle obligations joint venture europe gilead sciences ireland uc whollyowned subsidiary bms entered collaboration agreement sets forth terms conditions bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bmss estimated net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehousing local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling sales returns territories bms promote atripla general parties share revenues outofpocket expenses proportion net selling prices components atripla truvada efavirenz starting except limited number activities jointly managed parties longer coordinate detailing promotional activities european territory responsible accounting financial reporting tax reporting collaboration december efavirenz purchased bms bmss estimated net selling price efavirenz european territory included inventories consolidated balance sheets parties also formed limited liability company hold marketing authorization atripla european territory primary responsibility regulatory activities major market countries parties agreed independently continue use commercially reasonable efforts promote atripla agreement terminate upon expiration lasttoexpire patent affords market exclusivity atripla one components european territory addition since december either party may terminate agreement reason termination effective two calendar quarters notice termination nonterminating party right continue sell atripla become continuing party obligated pay terminating party certain royalties threeyear period following effective date termination event continuing party decides sell atripla effective date termination date atripla withdrawn country date third party assumes distribution atripla whichever earlier japan tobacco inc japan tobacco inc japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retained rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize elvitegravir treatment hiv infection bear costs expenses associated commercialization efforts received approval stribild elvitegravircontaining product fda august european commission may received approval genvoya elvitegravircontaining product fda european commission november agreement obligation pay royalties japan tobacco terminate productbyproduct basis patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement reason case license granted japan tobacco us would terminate either party may terminate agreement response material breach party janssen entered license collaboration agreement janssen sciences ireland uc janssen formerly tibotec pharmaceuticals develop commercialize fixeddose combination truvada janssens nonnucleoside reverse transcriptase inhibitor rilpivirine combination approved united states european union sold brand name complera united states eviplera european union original agreement janssen granted us exclusive license compleraeviplera worldwide excluding certain middle income developing world countries japan amended agreement include distribution compleraeviplera rest world amended agreement expand collaboration include another product containing janssens rilpivirine emtricitabine tenofovir alafenamide odefsey amended agreement janssen granted us exclusive license compleraeviplera odefsey worldwide retained rights distribute combination products countries including mexico russia japan neither party restricted combining drugs drug products except similar components compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization products except countries janssen distributes janssen exercised right codetail combination product countries gilead selling party initial agreement price compleraeviplera expected sum price truvada price rilpivirine purchased separately cost rilpivirine purchased us janssen compleraeviplera approximately market price rilpivirine less specified percentage major markets financial provisions amendment effective enable selling party set price combined products parties share revenues based ratio net selling prices partys components subject certain restrictions adjustments continue retain specified percentage janssens share revenues major markets either party may terminate collaboration agreement respect product country product withdrawn market country respect product countries party materially breaches agreement respect product agreement parties obligation share revenues expire productbyproduct countrybycountry basis janssen patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement without cause respect countries sell products case janssen right become selling party country product launched market fewer years galapagos closed license collaboration agreement galapagos clinicalstage biotechnology company based belgium development commercialization filgotinib jakselective inhibitor evaluated inflammatory disease indications upon closing license collaboration agreement made upfront license fee payment million million equity investment galapagos subscribing new shares price per share including issuance premium result received million new shares galapagos representing outstanding share capital closing license collaboration agreement license fee payment million issuance premium equity investment million recorded within research development expenses consolidated statements income equity investment net issuance premium recorded availableforsale security longterm assets consolidated balance sheets closing license collaboration agreement december december investment recorded prepaid current assets consolidated balance sheets galapagos eligible receive us development regulatory milestonebased payments million salesbased milestone payments million plus tiered royalties global net sales ranging exception certain copromotion territories profits would shared equally based achievement certain clinical development milestones recorded million expense within research development expenses consolidated statements income terms agreement exclusive worldwide royaltybearing sublicensable license filgotinib products containing filgotinib primarily responsible development seeking regulatory approval related filgotinib responsible galapagos responsible development costs incurred also responsible manufacturing commercialization activities galapagos exercised option co promote filgotinib certain territories territories galapagos share profits equally debt credit facilities following table summarizes carrying amount borrowings various financing arrangements millions december type borrowing issue date due date interest rate senior unsecured september september senior unsecured september september month libor term loan october october variable senior unsecured september march month libor senior unsecured march april term loan may may variable senior unsecured september september senior unsecured september september month libor senior unsecured november february senior unsecured september september term loan october october variable senior unsecured march april senior unsecured december december senior unsecured september march senior unsecured september september term loan october october variable senior unsecured september september senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march total debt net less current portion total longterm debt net senior unsecured notes connection acquisition kite issued billion aggregate principal amount senior unsecured notes registered offering consisting million principal amount floating rate notes due september million principal amount floating rate notes due march million principal amount floating rate notes due september collectively floating rate notes billion principal amount senior notes due september fixed rate notes collectively floating rate notes notes terms summarized table issued billion aggregate principal amount senior unsecured notes notes registered offering collectively refer notes notes senior unsecured notes issued september notes march november notes march december notes senior notes senior notes except floating rate notes may redeemed option redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus makewhole premium defined indenture senior notes maturing also call feature exercisable option redeem notes par whole part one six months immediately preceding maturity case accrued unpaid interest also required redeemed date redemption option redeem series floating rate notes whole part prior maturity date repaid maturity million principal balance related notes event occurrence change control downgrade rating senior notes investment grade moodys investors service inc sp global ratings holders may require us purchase portion notes price equal aggregate principal amount notes repurchased plus accrued unpaid interest date repurchase required comply certain covenants senior notes december violation covenants recognized billion million million interest expense senior notes related contractual coupon rates amortization debt discount issuance costs term loan facilities september entered billion aggregate principal amount term loan facility credit agreement consisting billion principal amount day senior unsecured term loan facility billion principal amount threeyear senior unsecured term loan facility billion principal amount fiveyear senior unsecured term loan facility collectively term loan facilities october drew billion principal amount term loan facilities used proceeds finance acquisition kite term loan facilities bear interest floating rates based libor plus applicable margin vary based debt ratings fitch ratings inc moodys investors service inc sp global ratings day senior unsecured term loan facility threeyear senior unsecured term loan facility due payable maturity fiveyear senior unsecured term loan facility payable quarterly amounts equal initial principal amount fiveyear senior unsecured term loan facility fiscal quarter end date second anniversary closing date remaining balance due payable maturity may prepay loans term loan facilities whole part time without premium penalty term loan facilities contain customary representations warranties affirmative negative financial maintenance covenants events default december violation covenants repaid billion principal balance related threeyear senior unsecured term loan facility million term loan facility issued may cash bridge facility august entered billion principal amount day senior unsecured term loan facility cash bridge facility cash bridge facility terminated result issuance notes entering term loan facilities september amounts drawn cash bridge facility convertible senior notes july issued billion convertible notes par private placement concurrent issuance convertible notes purchased convertible note hedges sold warrants private transactions portions convertible notes converted may remainder matured repaid aggregate principal balance million paid million cash related conversion spread convertible notes represented conversion value excess principal amount received million cash convertible note hedges related convertible notes paid million settle warrants average market price common stock exceeded warrants exercise price credit facilities terminated fiveyear billion revolving credit facility entered billion fiveyear revolving credit facility agreement maturing may fiveyear revolving credit agreement revolving credit facility used working capital requirements general corporate purposes including without limitation acquisitions december amounts outstanding fiveyear revolving credit agreement fiveyear revolving credit agreement contains customary representations warranties affirmative negative covenants events default december violation covenants loans fiveyear revolving credit agreement bear interest either eurodollar rate plus applicable percentage ii base rate plus applicable percentage defined fiveyear revolving credit agreement may terminate reduce commitments may prepay loans fiveyear revolving credit agreement whole part time without premium penalty contractual maturities financing obligations december aggregate future principal maturities financing obligations next five years based contractual due dates follows millions contractual maturities commitments contingencies lease arrangements lease facilities equipment related primarily administrative rd sales marketing activities various longterm noncancelable operating leases united states international markets leases expire various dates many leases containing options renew lease expense operating leases million million million aggregate noncancelable future minimum rental payments operating leases follows millions thereafter total legal proceedings party various legal actions significant described recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine loss reasonably possible loss range loss estimated disclose possible loss unless otherwise noted possible determine outcome matters reasonably estimate maximum potential exposure range possible loss recognize accruals litigation consolidated balance sheets december december believe losses probable litigation related sofosbuvir january acquired pharmasset inc pharmasset acquisition acquired sofosbuvir nucleotide analog acts inhibit replication hepatitis c virus hcv december received approval fda sofosbuvir known commercially sovaldi sofosbuvir also included marketed hcv products received number contractual intellectual property claims regarding sofosbuvir carefully considered claims prior following acquisition believe without merit predict ultimate outcome claims range loss except stated otherwise herein aware patents patent applications owned third parties may future alleged parties cover use hcv products third parties obtain valid enforceable patents successfully prove infringement patents hcv products could required pay significant monetary damages predict ultimate outcome intellectual property claims related hcv products spent continue spend significant resources defending claims interference proceedings litigation idenix pharmaceuticals inc idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversite montpellier ii february received notice us patent trademark office uspto declared interference first idenix interference us patent patent idenixs pending us patent application determine first invent certain nucleoside compounds january uspto patent trial appeal board ptab determined pharmasset idenix first invent compounds idenix acquired merck co inc merck august idenix appealed ptabs decisions us district court district delaware stayed appeal pending outcome appeal interference involving idenixs us patent patent described light decision second idenix interference favor described believe district court dismiss first idenix interference prejudice enter judgment idenix favor december receiving request uspto declared interference second idenix interference pending us patent application idenixs patent patent includes claims directed methods treating hcv nucleoside compounds march ptab determined pharmasset idenix first invent claimed methods treating hcv idenix appealed decision us district court district delaware us court appeals federal circuit cafc cafc heard oral arguments september affirmed ptab decision june november cafc denied idenixs petition rehearing idenix may file petitions united states supreme court filed motion dismiss appeal delaware granted idenix appealed dismissal cafc court stayed appeal pending decision second idenix interference believe appeal delaware dismissal dismissed light recent decision cafc affirming ptabs prior decision second idenix interference idenix entitled patent believe idenix claims involved first second idenix interferences similar us foreign patents claiming compounds metabolites uses thereof invalid result filed impeachment action federal court canada invalidate idenix canadian patent patent canadian patent corresponds patent idenix asserted commercialization sovaldi canada infringe patent canadian patent corresponding patent invalid november canadian court held idenixs patent invalid patent valid idenix appealed decision canadian federal court appeal november july canadian federal appeal court affirmed lower courts decision favor september idenix appealed decision supreme court canada january filed legal action federal court australia seeking invalidate idenixs australian patent corresponding patent april idenix asserted commercialization sovaldi australia infringes australian patent corresponding patent march australian court revoked idenixs australian patent idenix appealed decision december federal court australia dismissed idenixs appeal january idenix applied special leave appeal high court australia march european patent office epo granted idenix european patent patent corresponds patent day patent granted filed opposition epo seeking revoke patent opposition hearing held february epo ruled favor revoked patent idenix appealed march idenix also initiated infringement proceedings us united kingdom uk germany france alleging commercialization sovaldi would infringe uk german french counterparts patent trial held uk october december high court justice england wales uk court invalidated challenged claims patent multiple grounds idenix appealed november appeals court affirmed uk courts decision invalidating idenixs patent april uk supreme court refused idenixs application permission appeal march german court dsseldorf determined idenix patent highly likely invalid stayed infringement proceedings pending outcome opposition hearing held epo february idenix appealed decision german court staying proceedings upon idenixs request french proceedings stayed december idenix udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringe patent interference exists patent us patent also december idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringe us patent nos patent patent june court transferred massachusetts litigation us district court district delaware prior trial december idenix committed give us covenant sue respect claims arising patent related sofosbuvir withdrew patent trial addition idenix declined litigate patent infringement action trial light appeal pending cafc regarding first invent subject matter claimed patent january district court stayed idenixs infringement claim patent pending outcome appeal second idenix interference unless idenix successful persuading united states supreme court consider appeal challenge federal circuits june decision favor second idenix interference ask dismissal judgment entered idenix infringement interference claims jury trial held december remaining patent december jury found willfully infringed asserted claims patent awarded idenix billion past damages parties filed posttrial motions briefings district judge heard oral arguments september september judge denied idenixs motion enhanced damages attorneys fees february judge granted motion arguing patent invalid lacking enablement grant motion invalidating idenixs patent vacates jurys award billion past damages idenix indicated plans appeal decision cafc believe courts decision correctly found matter law patent invalid remain confident merits case appeal believe possibility material adverse outcome matter remote litigation merck august merck contacted us requesting pay royalties sales sofosbuvir obtain license us patent patent us patent patent coowns ionis pharmaceuticals inc patents cover compounds include may relate sofosbuvir filed lawsuit august us district court northern district california seeking declaratory judgment merck patents invalid infringed patent prosecution merck amended patent application attempt cover compounds related sofosbuvir initially march jury determined established mercks patents invalid lack written description lack enablement awarded merck million damages however june court ruled favor defense unclean hands determined merck may recover damages us patents judge determined merck required pay attorneys fees due exceptional nature case july court issued decision setting amount attorney fees awarded us merck filed notices appeal cafc regarding courts decision defense unclean hands award attorneys fees appealed issue relating invalidity mercks patent cafc heard oral arguments february decision defense unclean hands reversed appeal mercks patent upheld may required pay damages royalty sales sofosbuvircontaining products following appeal event judge indicated determine amount royalty necessary conclusion appeal case litigation university minnesota university minnesota university obtained patent patent purports broadly cover nucleosides antiviral anticancer activity august university filed lawsuit us us district court district minnesota alleging commercialization sofosbuvircontaining products infringes patent believe patent invalid infringed continued commercialization sofosbuvir october court granted motion transfer case california also filed four petitions inter partes review uspto alleging asserted claims invalid anticipation obviousness petitions inter partes review filed initiative medicines access knowledge october received notice initiative medicines access knowledge imak submitted multiple petitions requesting inter partes review ptab alleging certain patents associated sofosbuvir invalid either novel obvious strongly believe imaks petitions without merit sofosbuvir approved hcv drug kind novel obvious accordingly defend allegations ptab decides initiate one inter partes reviews decision would expected year later either party appeal ptabs decision cafc european patent claims february several parties filed oppositions epo requesting revocation one granted european patents covering sofosbuvir expires october epo upheld validity certain claims sofosbuvir patent appealed decision seeking restore original claims several original opposing parties also appealed requesting full revocation appeal process may take several years april several parties filed oppositions epo requesting revocation granted european patent relating sofosbuvir expires january several parties filed oppositions epo requesting revocation granted european patent covering tenofovir alafenamide taf expires july epo upheld validity claims taf patent awaiting written decision epo parties filed oppositions may appeal decision appeal process may take several years july several parties filed oppositions epo requesting revocation granted european patent relating taf hemifumarate expires march three parties filed oppositions epo requesting revocation granted european patent covering cobicistat expires december epo upheld validity claims cobicistat patent parties filed oppositions may appeal decision appeal process may take several years confident strength patents predict ultimate outcome oppositions unsuccessful defending oppositions patent claims may narrowed revoked patent protection sofosbuvir taf cobicistat european union could substantially shortened eliminated entirely patents revoked european patents granted covering compounds exclusivity may based entirely regulatory exclusivity granted european medicines agency sovaldi granted regulatory exclusivity prevent generic sofosbuvir entering european union years following approval sovaldi january lose patent protection sofosbuvir prior revenues results operations could negatively impacted years including succeeding year exclusivity lost may cause stock price decline litigation related axicabtagene ciloleucel october acquired kite whollyowned subsidiary acquisition acquired axicabtagene ciloleucel car cell therapy october received approval fda axicabtagene ciloleucel known commercially yescarta patents patent applications claim axicabtagene ciloleucel chimeric dna segments third parties may may obtain rights patents allegedly could used prevent attempt prevent us commercializing axicabtagene ciloleucel require us obtain license order commercialize axicabtagene ciloleucel example aware juno therapeutics inc juno exclusively licensed patent patent issued sloan kettering cancer center september juno sloan kettering cancer center filed lawsuit kite us district court central district california alleging commercialization axicabtagene ciloleucel infringes patent october following fda approval yescarta juno filed second complaint alleging axicabtagene ciloleucel infringes patent juno subsequently moved dismiss september complaint maintained october complaint august kite filed petition inter partes review uspto alleging asserted claims patent invalid obvious december ptab determined claims patent invalid due obviousness february kite filed notice appeal cafc appeal currently pending predict ultimate outcome intellectual property claims related axicabtagene ciloleucel junos patent upheld valid juno successfully proves infringement patent axicabtagene ciloleucel could prevented selling yescarta unless able obtain license patent license may available commercially reasonable terms litigation related bictegravir february viiv healthcare company viiv filed lawsuit us us district court delaware alleging commercialization bictegravir known commercially biktarvy infringes viivs us patent patent issued shinogi co ltd glaxosmithkline llc patent compound patent covering viivs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe claims patent extent viivs patent claims interpreted cover bictegravir believe claims invalid uspto granted us patents covering bictegravir february viiv also filed lawsuit us federal court canada alleging activities relating bictegravir product infringed viivs canadian patent patent issued shinogi co ltd viiv patent compound patent covering viivs dolutegravir believe bictegravir infringe claims patent extent viivs patent claims interpreted cover bictegravir believe claims invalid predict ultimate outcome intellectual property claims related bictegravir viivs patents upheld valid viiv successfully proves infringement patents bictegravir could required pay significant monetary damages litigation generic manufacturers part approval process products fda granted us new chemical entity nce exclusivity period manufacturers applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug sale generic versions products earlier patent expiration would significant negative effect revenues results operations seek approval generic version product nce status generic company may submit anda fda four years branded products approval current legal proceedings significance generic manufacturers include hiv products february received notice mylan pharmaceuticals inc mylan submitted anda fda requesting permission manufacture market generic version tybost cobicistat notice mylan alleges patent covering cobicistat invalid obvious mylans generic product infringe invalid claim march filed lawsuits mylan us district court district delaware us district court northern district west virginia parties agreed dismiss action west virginia trial delaware stayed patent suit covers tybost also listed orange book stribild genvoya november received notice mylan submitted anda fda requesting permission manufacture market generic version evotaz atazanavircobicistat challenging validity cobicistat compound patent citing arguments made ongoing litigation involving tybost december filed lawsuit mylan us district court northern district west virginia may received notice amneal pharmaceuticals llc amneal submitted anda fda requesting permission manufacture market generic version truvada low dosage strengths notice amneal alleges two patents associated emtricitabine invalid unenforceable andor infringed amneals manufacture use sale generic versions truvada low dosage strengths july filed lawsuit amneal us district court district delaware infringement patents june received notice macleods pharmaceuticals ltd macleods submitted andas fda requesting permission manufacture market generic versions truvada atripla notices macleods alleges two patents associated emtricitabine three patents associated emtricitabine tenofovir disoproxil fumarate tdf fixeddose combination three patents associated emtricitabine tdf efavirenz fixeddose combination invalid unenforceable andor infringed macleods manufacture use sale generic versions truvada atripla july filed lawsuit macleods us district court district delaware infringement patents december reached agreement macleods resolve lawsuit settlement agreement filed federal trade commission department justice required law hcv products february received notices natco pharma limited natco teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version sovaldi tevas notice alleges nine patents associated sofosbuvir invalid unenforceable andor infringed tevas manufacture use sale generic versions sovaldi natcos notice alleges two patents associated sofosbuvir invalid unenforceable andor infringed natcos manufacture use sale generic versions sovaldi natco challenge patents listed orange book sovaldi evaluating notice letters determining next steps taf litigation january aids healthcare foundation inc ahf filed complaint us district court northern district california gilead japan tobacco inc japan tobacco international usa together jt emory university emory april ahf amended complaint add janssen johnson johnson inc jj defendants ahf claims us patent nos invalid addition ahf claims gilead independently together jt akros janssen jj violating federal state antitrust unfair competition laws market sales taf offering taf part fixeddose combination product elvitegravir cobicistat emtricitabine genvoya fixeddose combination product elvitegravir rilpivirine odefsey fixeddosed combination product elvitegravir descovy ahf sought declaratory judgment invalidity patents well monetary damages may jt janssen jj filed motions dismiss ahfs claims ahf opposed june hearing held motions dismiss july judge granted defendants motions dismissed ahfs claims ahf subsequently appealed courts decision dismissing challenge validity taf patents appeal hearing held june awaiting decision government investigations related litigation june received subpoena us attorneys office northern district california requesting documents related manufacture related quality distribution practices complera atripla truvada viread emtriva hepsera letairis cooperated governments inquiry april us department justice informed us following investigation declined intervene false claims act lawsuit filed two former employees april former employees served first amended complaint january federal district court issued order granting entirety without prejudice motion dismiss first amended complaint february plaintiffs filed second amended complaint june federal district court issued order granting motion dismiss second amended complaint july plaintiffs filed notice appeal us court appeals ninth circuit july threejudge panel ninth circuit reversed remanded case back us district court northern district california october ninth circuit granted motion stay case pending appeal supreme court united states december filed petition writ certiorari supreme court expect supreme court decide whether hear case later year february received subpoena us attorneys office district massachusetts requesting documents related support c organizations provide financial assistance patients documents concerning provision financial assistance patients hcv products cooperating inquiry october received subpoena us attorneys office district massachusetts requesting documents related copay coupon program medicaid price reporting methodology cooperating inquiry september received voluntary request information us attorneys office eastern district pennsylvania requesting information related reimbursement support offerings clinical education programs interactions specialty pharmacies sovaldi harvoni cooperating voluntary request october received subpoena california department insurance alameda county district attorneys office requesting documents related marketing activities reimbursement support offerings clinical education programs interactions specialty pharmacies cooperating inquiry november health choice advocates llc served us complaint united states district court eastern district texas alleging violations false claims act similar state statutes marketing activities reimbursement support offerings clinical education programs sovaldi harvoni lawsuit unsealed united states plaintiffstates declined intervene action evaluating next steps november received subpoena us department health human services requesting documents related frontlines communities united states focus program cooperating inquiry november also received subpoena us attorneys office southern district new york requesting documents related promotional speaker programs hiv cooperating inquiry matters party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations commitments normal course business enter various firm purchase commitments primarily related active pharmaceutical ingredients certain inventory related items december commitments next five years approximately million million million million million amounts related active pharmaceutical ingredients represent minimum purchase commitments actual payments purchases related active pharmaceutical ingredients billion billion billion stockholders equity stock repurchase programs first quarter board directors authorized billion stock repurchase program program repurchases may made open market privately negotiated transactions program commenced billion stock repurchase program authorized board directors january program completed second quarter billion stock repurchase program authorized board directors may program completed first quarter repurchased retired million shares common stock million open market transactions program december remaining authorized repurchase amount program billion february entered accelerated stock repurchase program asr repurchase billion common stock program made upfront payment billion received million shares common stock million shares represented approximately total shares calculated based common stock closing price per share date entered asr april asr settled received additional million shares common stock based average price common stock asr purchase period less predetermined discount result average purchase price common stock asr per share accounted asr two separate transactions shares common stock acquired treasury stock transaction recorded transaction date b forward contract indexed common stock upfront payment billion accounted reduction stockholders equity consolidated balance sheets period payment made asr met applicable criteria equity classification therefore accounted derivative instrument shares received asr retired periods received following table summarizes stock repurchases abovedescribed programs millions except per share data year ended december shares repurchased retired amount average price per share notes repurchases program includes million shares repurchased billion program million shares repurchased billion program includes million shares repurchased billion program million shares repurchased billion program addition repurchases stock repurchase programs repurchased shares common stock withheld us employee restricted stock awards satisfy applicable tax withholding obligations immaterial excluded table use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated apic based estimated average sales price per issued share excess amounts charged retained earnings following table summarizes reduction common stock apic charge retained earnings result stock repurchases millions year ended december reduction common stock apic charge retained earnings dividends following table summarizes cash dividends declared common stock millions except per share data dividend per share amount dividend per share amount first quarter second quarter third quarter fourth quarter total restricted stock performancebased stock units dividend equivalent rights entitling holders dividend equivalents paid upon vesting share underlying units february announced board directors declared quarterly cash dividend per share common stock payment date march stockholders record close business march future dividends subject declaration board directors preferred stock million shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series preferred stock outstanding december accumulated comprehensive income following table summarizes changes aoci component net tax millions unrealized gains losses unrealized gains foreign currency availableforsale losses translation securities cash flow hedges total balance december comprehensive income reclassifications amounts reclassified accumulated comprehensive income net current period comprehensive income balance december comprehensive income loss reclassifications amounts reclassified accumulated comprehensive income net current period comprehensive income loss balance december amounts reclassified gains losses cash flow hedges recorded part product sales consolidated statements income see note derivative financial instruments additional information amounts reclassified gains losses availableforsale securities recorded part income expense net consolidated statements income employee benefits provide share based compensation form various types equitybased awards including restricted stock units rsus performancebased restricted stock units psus stock options compensation expense recognized consolidated statements income based estimated fair value award grant date estimated fair value rsus based closing price common stock psus estimated fair value based either monte carlo valuation methodology stock price date grant stock option awards estimated fair value based blackscholes option valuation model equity incentive plan may stockholders approved adopted gilead sciences inc equity incentive plan amended plan plan broad based incentive plan provides grant equitybased awards including stock options restricted stock units restricted stock awards performance awards employees directors consultants plan authorized issuance total million shares common stock may maximum number shares may issued plan increased million shares december total million shares remain available future grant plan stock options plan provides option grants designated either nonqualified incentive stock options prior january granted nonqualified incentive stock options stock options granted january nonqualified stock options plan employee stock options granted prior generally vest five years stock options granted starting generally vest four years options exercisable period exceed contractual term ten years date stock options issued granted prices less fair market value common stock grant date stock option exercises settled common stock plans previously authorized available pool shares following table summarizes activity related information stock option plans option grants presented table except kite related replacement awards exercise prices less fair value underlying common stock grant date weighted weightedaverage aggregate average remaining intrinsic shares exercise price contractual term value thousands dollars years millions outstanding december granted grantedreplacement awards forfeited expired exercised outstanding december exercisable december expected vest net estimated forfeitures december note connection acquisitions kite cell design labs replaced unvested kite cell design labs stock options stock options options fair valued using lattice valuation methodology see note acquisitions additional information aggregate intrinsic value represents value closing stock price last trading day year excess weightedaverage exercise price multiplied number options outstanding exercisable total intrinsic value options exercised million million billion weightedaverage grant date fair value stock options granted per share per share per share december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years performancebased restricted stock units plan grant psus vest upon achievement specified market performance goals could include achieving total shareholder return compared predetermined peer group achieving revenue targets actual number common shares ultimately issued calculated multiplying number psus payout percentage ranging awards generally vest committee subcommittee board determined specified market performance goals achieved fair value psu estimated date grant performance objectives defined grants depending terms award fair value date grant determined based either monte carlo valuation methodology closing stock price date grant addition also granted psus certain employees plan vesting awards subject achievement specified individual performance goals typically within one year period fair value award equal closing price common stock grant date following table summarizes activity related information psus weighted average grant date fair value per shares share thousands dollars outstanding december granted vested forfeited outstanding december note weightedaverage grantdate fair value per share excludes shares related grants currently grant date performance objectives yet defined weightedaverage grant date fair value psus granted per share per share per share total grant date fair value vested psus million million million total fair value respective vesting dates million million million recognized stockbased compensation expenses million million million related psus december million unrecognized compensation costs related psus expected recognized estimated weightedaverage period years restricted stock units grant timebased rsus certain employees part annual employee equity compensation review program well new hire employees nonemployee members board rsus share awards entitle holder receive freely tradable shares common stock upon vesting rsus generally vest four years date grant fair value rsu equal closing price common stock grant date following table summarizes rsu activities related information weighted average grant date fair value per shares share thousands dollars outstanding december granted grantedreplacement awards vested forfeited outstanding december note connection acquisition kite replaced unvested kite restricted stock units restricted stock units estimated fair value date replacement based closing price common stock date see note acquisitions additional information weightedaverage grant date fair value rsus granted per share per share per share total grant date fair value vested rsus million million million total fair value respective vesting dates million million million december million unrecognized compensation cost related unvested rsus expected recognized weightedaverage period years employee stock purchase plan employee stock purchase plan international employee stock purchase plan together amended espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date prior espp offered twoyear lookback feature well automatic reset feature provides offering period reset new lowerpriced offering offering price new offering period less current offering period beginning first quarter lookback feature espp offering periods became sixmonths espp purchases settled common stock espps previously authorized available pool shares million shares issued espp million total million shares common stock authorized issuance espp million shares available issuance espp december stockbased compensation following table summarizes total stockbased compensation expenses included consolidated statements income millions year ended december cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense net tax capitalized stockbased compensation costs inventory totaling million million million capitalized stockbased compensation costs remaining inventory million december million december million december stockbased compensation recognized expense requisite service periods consolidated statements income using straightline expense attribution approach reduced estimated forfeitures estimate forfeitures based historical experience valuation assumptions fair value options granted plan purchases espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life used following assumptions calculate estimated fair value awards year ended december expected volatility stock options espp expected term years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted calculated using single option approach use blend historical volatility along implied volatility traded options common stock determine expected volatility expected term stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected term based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts deferred compensation maintain retirement saving plan eligible us employees may defer compensation income tax purposes section k internal revenue code gilead sciences k plan certain foreign subsidiaries maintain defined benefit plans required local regulatory requirements total matching contribution expense gilead sciences k plan defined benefit plans million million million maintain deferred compensation plan directors key employees may defer compensation amounts deferred participants deposited rabbi trust total assets liabilities associated deferred compensation plan million december million december net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding period diluted net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding dilutive securities outstanding period potentially dilutive shares common stock resulting assumed exercise outstanding stock options equivalents assumed conversion outstanding convertible notes assumed exercise warrants related outstanding convertible notes determined treasury stock method convertible notes associated warrants settled excluded stock options equivalents approximately million million million weightedaverage shares common stock outstanding respectively computation diluted net income per share attributable gilead common stockholders effect antidilutive following table shows calculation basic diluted net income per share attributable gilead common stockholders millions except per share amounts year ended december net income attributable gilead shares used per share calculation basic effect dilutive securities stock options equivalents conversion spread related convertible notes warrants related convertible notes shares used per share calculation diluted net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders diluted segment information one operating segment primarily focuses discovery development commercialization innovative medicines areas unmet medical need therefore results operations reported consolidated basis consistent internal management reporting reviewed chief operating decision maker chief executive officer enterprisewide disclosures product sales revenues longlived assets geographic area revenues major customers presented product sales product sales consist following millions year ended december antiviral products harvoni genvoya epclusa truvada atripla descovy stribild viread odefsey compleraeviplera sovaldi vosevi antiviral total antiviral products products letairis ranexa ambisome zydelig products total product sales revenues geographic region following table summarizes total revenues external customers collaboration partners geographic region millions product sales productrelated contract revenue attributed regions based shipto location royalty nonproduct related contract revenue attributed regions based location collaboration partner year ended december revenues united states europe countries total revenues longlived assets net book value property plant equipment less office computer equipment united states billion december billion december billion december corresponding amount international locations million december million december million december individual international locations accounted less ten percent total balances revenues major customers following table summarizes revenues customers individually accounted total revenues percentage total revenues year ended december mckesson corp amerisourcebergen corp cardinal health inc income taxes income provision income taxes consists following millions year ended december domestic foreign total income provision income taxes provision income taxes consists following millions year ended december federal current deferred state current deferred foreign current deferred provision income taxes december tax cuts jobs act tax reform signed law making significant changes internal revenue code amended changes include limited corporate tax rate decrease effective tax years beginning december implementation modified territorial tax system repatriation tax deemed repatriated earnings foreign subsidiaries calculated provisional estimate impact tax reform income tax provision accordance interpretation tax reform guidance available date filing result recorded estimated billion net charge income tax expense fourth quarter period tax reform enacted amount includes provisional million deferred tax benefit related remeasurement certain deferred tax assets liabilities based revised rates expected reverse future ii provisional billion charge related transition tax mandatory deemed repatriation accumulated foreign earnings determined december provisional transition tax charge includes federal net certain offsetting adjustments related unrecognized tax benefits state local foreign withholding tax accumulated foreign earnings longer considered indefinitely reinvested december accrued federal liability transition tax billion payable eight year period december million transition tax recorded within accrued liabilities billion recorded longterm income taxes payable consolidated balance sheets accordance us securities exchange commission sec staff accounting bulletin sab determined million deferred tax benefit recorded connection remeasurement certain deferred tax assets liabilities billion current tax expense recorded connection transition tax mandatory deemed repatriation foreign earnings provisional subject adjustment measurement period exceed one year enactment tax reform given complexity tax reform may refining estimates provisional amounts guidance issued us treasury sec fasb february repatriated billion cash cash equivalents marketable securities parent company headquartered united states prior enactment tax reform earnings considered indefinitely reinvested us taxes provided us taxes provided earnings accrual tax reform transition tax additionally continuing evaluate accounting policy election required regard tax global intangible lowtaxed income global minimum tax fasb allows companies adopt policy election account global minimum tax one two methods account global minimum tax component tax expense period company subject rules period cost method ii account global minimum tax companys measurement deferred taxes deferred method elected method completion analysis global minimum tax provisions election method depend part analyzing expected future us taxable income inclusions related global minimum tax methodologies order determine appropriate method decide elect deferred method accounting global minimum tax possible provisional estimate remeasuring deferred taxes may materially change finalize analysis accounting policy election measurement period reconciliation federal statutory tax rate applied income taxes effective tax rate summarized follows year ended december federal statutory rate state taxes net federal benefit foreign earnings different rates research credits transition tax deferred tax revaluation effective tax rate deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows millions december deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible deferred revenue depreciation related research credit carryforwards net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities intangibles total deferred tax liabilities net deferred tax assets liabilities valuation allowance million december million december million december increase valuation allowance december december primarily related kite december us federal net operating loss carryforwards approximately billion federal net operating loss carryforwards start expire utilized also federal tax credit carryforwards approximately million start expire utilized addition state net operating loss tax credit carryforwards approximately million million respectively state net operating loss tax credit carryforwards start expire utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization file federal state foreign income tax returns united states many foreign jurisdictions federal california income tax purposes statute limitations open onwards certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years income tax returns subject audit federal state foreign tax authorities currently examination irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions total unrecognized tax benefits billion december recognized would reduce effective tax rate period recognition continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements income accrued interest penalties related unrecognized tax benefits million december million december december believe reasonably possible unrecognized tax benefits decrease approximately million next months due potential settlement tax examinations lapse statute limitations following rollforward total gross unrecognized tax benefits millions december balance beginning period tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance end period selected quarterly financial information unaudited following amounts millions except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales net income loss net income loss attributable gilead net income loss per share attributable gilead common stockholders basic net income loss per share attributable gilead common stockholders diluted total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders diluted note december recorded estimated billion net charge related enactment tax cuts jobs act see note income taxes notes consolidated financial statements included item annual report additional details gilead sciences inc schedule ii valuation qualifying accounts millions balance beginning additionscharged balance end period expense deductions period year ended december accounts receivable allowances sales return allowance valuation allowances deferred tax assets year ended december accounts receivable allowances sales return allowance valuation allowances deferred tax assets year ended december accounts receivable allowances sales return allowance valuation allowances deferred tax assets notes allowances doubtful accounts cash discounts chargebacks valuation allowances deferred tax assets include million million million december respectively related acquisitions item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae securities exchange act amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commissions rules forms information accumulated communicated companys management including chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective december b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included item annual report issued report internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting report independent registered public accounting firm stockholders board directors gilead sciences inc opinion internal control financial reporting audited gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework coso criteria opinion gilead sciences inc company maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states pcaob consolidated balance sheets company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes financial statement schedule listed index item report dated february expressed unqualified opinion thereon basis opinion companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate ernst young llp redwood city california february item b information applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings nominees board structure executive officers section beneficial ownership reporting compliance written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwgileadcom investors section corporate governance changes waivers code ethics disclosed website intend satisfy disclosure requirement item form k regarding amendment waiver provision code ethics disclosing information website item executive compensation information required item incorporated reference sections proxy statement headings executive compensation committees board directors compensation committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference sections proxy statement headings security ownership certain beneficial owners management securities authorized issuance equity compensation plans item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings gilead board directors board processes item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services part iv item